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1Introduction
Aerosolised drugs are nowadays cornerstones in the treatment of pulmonary diseases.
Although the use of inhaled drugs is known for some centuries, the break-through of
this mode of administration was only a few decades ago. The metered dose inhaler
(MDI) was the first apparatus, which is both reliable and practical. Previously, all kind
of nebulisers were availble, but their size prevented (and still prevents) outdoor use.
The use of MDI's resulted in a decreased need for systemically administered broncho-
dilators or other anti-asthma drugs. This meant a considerable reduction of side-
effects and an improvement of the quality of therapy1. The growing experience with
MDI's revealed some drawbacks of the system: it appeared that a considerable num-
ber of patients were not able to use a MDI correctly2. Many authors pointed out that
several mistakes were possible, like failing hand-lung co-ordination, stopping an i-
halation after firing the MDI. These mistakes cause a suboptimal delivery of drugs to
the airways and thereby a reduced therapeutic efficacy. To cope with these problems,
spacers were introduced and somewhat later dry powder inhalers. At this moment a
broad spectrum of aerosol generators is available, the latest development being a
breath actuated MDI3.
It became also known that only a small fraction (10-20%) of the emitted dose reaches
the lower airways. The remainder deposits in the extrathoracic and upper airways, is
swallowed and subsequently absorbed in the gastrointestinal tract4. This low vail-
ability is related to the formulation of the aerosols. All aerosol generators produce
particles (or droplets) with a wide range of diameters. Such aerosols are defined as
polydisperse, opposite to monodisperse aerosols, of which the diameter range is
small. Large particles tend to deposit in the extrathoracic and upper airways; size
measurements of the particles produced by all current generators reveal that the ma-
jority of the particles generated are these large particles5.
To increase the efficacy of the administration, it is evident that the formulations of
these aerosols have to be improved to increase lung deposition and to decrease ex-
trathoracic and upper airway deposition. In general, the smaller a particle is the lower
the extrathoracic and upper airway deposition will be and the deeper it penetrates the
2lower airways. However, the tendency to deposit declines as particle size decreases.
Therefore, a particle may not be too large or too small.
A confounding parameter is the diameter of the airways. In small tubes a smaller par-
ticle shall penetrate further due to its lower deposition tendency, while in larger tubes
such a low tendency proves to be the wrong choice. An absence of deposition is
equivalent to a lack of therapeutic effect. Transferred to therapeutic aerosols in asth-
matic patients the ideal formulation may depend on the degree of constriction of the
airways. The localisation of receptors may also be of influence. Barnes showed that
more ß2-receptors are present in small airw ys compared to large airways6. Hence it
may be hypothesised that ß2-mimetic aerosols should be directed towards the periph-
ery of the lung and therefore should ex ibit a small particle size.
The subject of this thesis is the definition of the most efficient aerosol formulation in
terms of particle size or what is the most efficient formulation of a bronchodilator
aerosol  in patients exhibiting increasing degrees of bronchoconstriction.
This thesis will start with an overview of existing knowledge on deposition of aero-
sols. A review of the theoretical and physical backgrounds of deposition is offered in
chapter 2 and on the measurements of lung deposition of non-therapeutic and thera-
peutic aerosols in chapter 3 and 4 respectively. In chapter 5 the goals of the experi-
ments, described in this thesis will be explained in greater detail and in subsequent
chapters the results.
3Literature
1 Timsina M.P., Martin G.P., Marriott C., Ganderton D. and Yianneskis M.
Drug delivery to the respiratory tract using dry powder inhalers.
Int J Pharm 101: 1-13 1994.
2 Pedersen S., Frost L. and Ar fred T.
Errors in inhalation technique and efficiency in inhaler use in asthmatic children.
Allergy 41: 118-124 1986.
3 Newman S.P., Weisz A.W.B., Talaee N. and Clarke S.W.
Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler
technique.
Thorax 46: 712-716 1991.
4 Biddiscombe M.F., Melchor R., Mak V.H.F., Marriott R.J., Taylor A.J., Short M.D. and Spiro
S.G.
The lung deposition of salbutamol, directly labelled with technetium-99m, delivered by pressurised m-
tered dose and dry powder inhalers.
Int J Pharm 91: 111-121 1993.
5 Bouchikhi A., Becquemin M.H., Bignon J., Roy M. and Teillac A.
Particle size study of nine metered dose inhalers and their deposition probabilities in the airways.
Eur J Respir 1: 547-552 1988.
6 Barnes P.J., Basbaum C.B., Nadel J.A. and Roberts J.M.
Localization of ß-adrenoreceptors in mammalian lung by light microscopic autoradiography.
Nature 299: 444-447 1982.
1Predictive models of lung deposition
Introduction
In the last part of the 19th century mining companies started to realise that inhaled
dust caused the frequently occurring pneumoconiosis in miners. Watkins-Pitchford
and Muir reported that approx. 80% of all silica particles in the lungs of patients were
<2 mm1. Mavrogordato launched the idea that the particles <5 mm, but >0.5 mm
caused pneumoconiosis2.
So a hypothesis emerged: a relation exists between particle size and penetration of
dust into the lungs, but more research was needed to reject or accept this hypothesis.
Unfortunately at that moment, measuring lung deposition of inhaled particles was
technically impossible and researchers had to find an alternative: mathematical model-
ling. Physicists, studying the deposition of particles in straight tubes, revealed deposi-
tion-mechanisms and formulated some equations. To learn on the deposition in the
human airways the ideal straight tube was replaced by a system of tubes, resembling
the human airways. Knowing the complexity of the airways, the difficulty of these
calculations is conceivable and simplifications unavoidable. In the sections below we
will discuss one of the models in some detail, because it serves as good introduction
into deposition mechanisms. Moreover, it is well established and elaborated.
Deposition model of Findeisen
In 1935 Findeisen published his ‘Uber das Absetzen kleiner in der Luft suspendierter
Teilchen in der mensliche Lunge b i der Atmung’, in which he revealed his methods3.
The model was based on the presence of four deposition-mechanisms: a] impact on,
b] sedimentation, c] Brownian movement and d] the so called 'rim-effect'.
a] Impaction. Along its travel through the airways, a flow of air changes direc-
tion often and suddenly. Due to their inertia, particles shall not always be able to fol-
low these changes, causing them to collide with the wall of the airways. The general
character of deposition by impaction is: large particles travelling at high speed exhibit
the highest probability of deposition. In the human airways the velocity of the air is
2highest in the upper airways, therefore impaction is n important deposition mecha-
nism in these parts. In other words, large particles are f ltered out of the air in the up-
per airways.
b] Sedimentation. Due to gravity, particles will start to fall. At the moment the
force of gravity equals the air resistance, the speed becomes constant: the so called
terminal velocity. High terminal velocities are equivalent to high deposition-
probabilities, because such particles travel larger distances i  an unit of time. These
higher velocities are found with the larger particles. Because the residence time is too
short, sedimentation is of lesser importance in the upper airways. Sediment tion
therefore causes particles, who ‘escaped’ impaction, to deposit in the smaller airways.
An important aspect of sedimentation is, when particle-size reduces, the terminal ve-
locity reduces too. So small particles need more time to reach the walls of the bronchi
and when that time exceeds one complete breathing-cycle, the partiles are xhaled.
Increasing the volume of air inhaled and breath-holding are both important, because
they both increase the residence time.
c] Brownian movement. Due to collisions with air molecules, very small par-
ticles (<0.01 µm) start to move in a random manner over random distances and a
chance is present of a collision with the walls of the bronchi. It will be clear that only
very small particles deposit efficiently by Brownian moveme t.
d] Rimeffect. By pure chance it is possible that a particle, in close vicinity of the
wall touches it and deposits. Findeisen called that the 'rim-effect'. In the calculations
the contribution of this effect to the total deposition turned out to be negligible.
To keep calculations at a practical level, the anatomy of the human airways was sim-
plified considerably: it was restricted to only 9 airway generations. Find isen also re-
stricted his calculations to just one breathing volume and inhalation-flow. The out-
come is presented in  Fig.1. The conclusions are clear: large particles deposit entirely
(in the upper airways). Smaller particles do penetrate further, but the tendency to de-
posit reduces as they decrease in size. The deposition of 0.1-0.3 mm particles is mini-
mal. These particles do not deposit by impaction any more, their terminal velocity is
very low, while they are still too heavy for Brownian movement deposition.
3From a protective point of view this is a desired effect. The alveoli do not possess a
fast and effective clearance mechanism and must therefore be protected against (in-
soluble) inhaled particles. Large particles contain more mass then small ones and can
be more toxic. It is therefore crucial that large particles are filtered out in those parts
of the airways where they are quickly removed. Smaller particles are of less immediate
danger: they deposit to a small extent and their mass is low. Due to their ability to
penetrate deeper in the airways, they form a danger over a large period of time.
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Fig. 1 Total lung deposition (= particles entering minus particles leaving the
airways) as calculated by Findeisen3
In later years this first and crude model was refined. Landahl increased the number of
bronchioli, alveolar ducts and alveoli considerably, redefined the deposition-equations
and added to the model the influence of increasing breathing volumes4. The res lts of
these calculations are presented in Fig. 2. Compared to Findeisen, the deposition rate
for larger particles is somewhat lower, but the general character remains the same. A
larger inhaled volume leads to an increased deposition (especially for small particles),
while a fast inhalation favours proximal deposition.
4A second improvement by Beeckmans was the incorporation of the Weibel-A lung-
model5 6. The Weibel-A model is based on measurements of airways dimensions in
casts of human airways and is more accurate. The higher accuracy of the Weibel-A
model, however, did not improve the fit to the experimental data. Despite this minor
improvement Beeckmans prefered the Weibel-A model on theoretical grounds and in
later publications the model is commonly used.
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Fig. 2 Total deposition as function of i halationflow and -volume, calculated by
Landahl4
In 1966 a significant contribution to the modelling was published by the Task Group
of the International Committee on Radiological Protection (IRCP)7. This Task Group
had to formulate a model to estimate the deposition and especially the clearance from
the lungs of radioactive dust. A very practical application for which it became famous.
The Group did not design a new model, but modified/improved the Findeis n/Landahl
model. First, one defined three compartments: 1] nasopharyngeal, 2] tracheobronchial
and 3] alveolar or pulmonary. From a clearance point of view, these compartments
behave differently. Compartment 1] and 2] possess ciliated epithelium, which can re-
move insoluble deposited particles quickly, while the alveolar compartment can not. A
second improvement is the use of the so called aerodynamic particle size. In all cal-
culations up to now, spherical particles were 'used', but these are rare in nature. The
5terminal velocity of a particle also depends on its shape: needle shaped crystals show
higher velocities. The definition of the aerodynamic size of a particle is: the size of a
spherical particle with a mass of 1, having the same terminal velocity of said parti-
cle. In other words, every irregular shaped particle is transformed to a spherical one
by comparing terminal velocities. The aerodynamic particle size is now standard in
aerosol-sizing. The third change was the implementation of polydisperse aerosols in
modelling. Natural aerosols exhibit a range of sizes (polydisperse) and as result, depo-
sition therefore is expected to be widespread in the airways. In Table 1 results on the
deposition of polydisperse aerosols are presented. From the data it is clear that the
increasing polydispersity of 'large' aerosols poses a threat in terms of alveolar deposi-
tion. Large aerosols were not supposed to reach the alveoli and therefore they could
not damage alveolar tissues. This is, however, only correct as long as the aerosols are
monodisperse (=show a narrow size-distribution).
MAD
(mm) s
Nasopharyngeal
deposition
Tracheobronchial
deposition Pulmonary deposition
0.2 1.2 0.00 2.06 36.4
0.2 1.5 0.01 2.37 39.1
0.2 2.0 0.78 2.91 41.2
0.2 2.5 2.36 3.61 42.3
0.2 3.0 4.09 4.24 42.8
2 1.5 51.1 4.70 27.2
2 2.0 50.7 4.30 23.6
2 2.5 50.4 3.90 21.8
2 3.0 50.2 3.61 21.0
2 4.0 50.1 3.57 20.6
20 1.2 99.9 0 0
20 2.5 97.2 0.81 1.70
20 3.0 95.6 1.03 2.60
Table 1 Percentual deposition of polydisperse aerosols, according to the IRCP
Task Group7. MAD = median aerodynamic diameter, s = geometric standard deviation
6Following the work of the Task Group deposition-modelling is characterised by a
steady addition of parameters, thereby increasing the complexity of the Fin-
disen/Landahl/ Beeckmans model. We will discuss some of these added parameters.
Deposition due to turbulence
All the previous models were based on the assumption that airflows are laminar. This
is of course only true in small airways and Yeh feared an underestimation of the depo-
sition due to negligence of turbulent deposition8. Yeh, however, states that only depo-
sition by Brownian movement is affected by turbulence and formulates a set of equa-
tions, based on heat-transfer processes. Unfortunately no results are given, only the
methods. A second attempt was made by H mill, based on the studies on deposition
under turbulent flow conditions by Friedlander and Johnstone9 10. Hamill's results in-
dicate that turbulent deposition is a typical large particle phenomenon, but ten times
less efficient as impaction itself.
Regional deposition
Findeisen attempted to calculate the deposition per individual airway-generation, but
his rather crude lung-model prevented accurate conclusions. Based on the Landahl
equations and the Weibel-A model Gerrity made a second attempt11. In Fig. 3 the r-
sults are presented. In general one can say that large particles deposit in the proximal
airways and small ones in distal. Important to note is that deposition patterns are al-
ways widespread. Large particles do reach the distal airways in low numbers. So
when an abundant number of large particles are inhaled, the burden to the alveoli can
still be significant.
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Fig. 3 Calculated regional deposition of 1 µm, 2 µm, 3µm, 5 µm, 7 µm and 10
µm non-hygroscopic particles11
Yeh and Schum measured the dimensions of human airways based on a cast of them.
The advantage of this model is the possibility to calculate the deposition per lobe in
stead of per airway generation (the Weibel-A model does not posses lung-lobes)12. In
Table 2 the results are presented. It is clear that significant differences between the
deposited amount of particles in the lobes exist. Anatomical differences are held r-
sponsible.
8d(mm) region UR MR LR UL LL
TB 0.32 0.14 0.62 0.33 0.68
1
P 1.91 1.01 3.40 1.69 0.32
TB 0.56 0.25 1.12 0.57 1.21
2
P 2.85 1.50 5.17 2.57 5.02
TB 0.79 0.37 1.61 0.80 1.74
3
P 3.09 1.63 5.66 2.83 5.50
Table 2 Percentual deposition per lung lobe, according to Yeh and Schum12.
UR= upper right, MR = middle right, LR = lower right, UL = upper left, LL = lower left, TB = tracheo-
bronchial, P = pulmonary, d = aerodynamic particle size
Hygroscopy
Particles that enter the airways, are exposed to an atmosphere of approx. 99% relative
humidity. Insoluble particles shall be surrounded by a layer of water, while soluble
particles will absorb water until the fluid is isotonic. The effect is particle-growth.
Hypo-osmolar droplets will, however, decrease in size, because they give off water
until an equilibrium is reached. Austin was one of the first to address this problem13.
The changes in particle size, the place and the extent of deposition depends on the
residence time and the speed at which the equilibrium is reached. A comparison with
experimental data showed that Austin's model underestimates the deposition, most
probably due to flawed estimates of the point, where the particle growth/evaporation
equilibrium is reached.
A second attempt was made by Martonen14. His objectives were to calculate the depo-
sition of hygroscopic H2SO4-aerosols, which are a part of the daily airpol ution and
occur as small particles. Based on the Weibel-A model and Landahls' equations, he
calculated the deposition patterns of these droplets under varying airway humidity
conditions (50% to 100%). The results indicate that, under 100% relative humidity
conditions, 1 mm particles grow into 16 mm droplets, causing them to deposit much
more quickly by impaction. If the relative humidity is 90% the equilibrium size is ap-
prox. 2.2 mm. Smaller particles (0.1 mm) grow to a final size of 0.7 mm and 0.2 mm
9respectively. The changes in deposition are less extreme for these particles, as can be
expected from the limited size changes.
Age
Children grow and growth is equivalent a continuous enlargement of the airways,
both in length and diameter. These changes must have an effect on particle deposition.
To find out how large the effects of ageing are, Schum scaled the W ibel-A model
down to dimensions encountered in different age groups and calculated the deposi-
tion. In 2 year old children 23.8% of 1 mm particles deposit, while in 20 years old
adults only 10.4% of them deposit. The general trend is that in larger airways particles
deposit less well, as a function of increasing age. This is particularly true for particles
>1 mm, which deposit by sedimentation or impaction15.
Deposition in constricted airways
Up to now, the deposition of particles is modelled in a 'healthy' lung-model. Kim and
co-workers developed a lung-model, based on the Weib l-A model, in which the air-
ways were constricted to estimate the deposition in diseased airways16. They de-
creased the airway diameter with 25% or 40% in either peripheral or central airways.
The next step was to calculate the increase in resistance and deposition. In Fig. 4 the
results are presented. As can be concluded from the graphs, there is no simple relati-
onship between the increase in deposition and resistance. Except when peripheral air-
ways are constricted, the increase in resistance is always higher than in deposition, but
not by a constant factor. This is to be expected, because the resistance relat  to the
airway-diameter by the fourth power and the deposition does not. The deposition in-
crease occurs mainly in the large airways, while it decreas s in the small airways (gen-
eration 14 and up). This can be explained by the higher filter efficiencies of the con-
stricted upper airways.
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Fig. 4 Percentage increase of resistance and deposition of 3 µm particles after
reducing airway diameter with 25% or 40%16. The upper graph represents the situation
after a diameter reduction of 25%, the lower one after a 40% reduction
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1In-vivo measurements of lung deposition
Introduction
By using mathematical models, as described in the previous chapter, much knowledge
was gained on the deposition of particles in the airways. However, models can not
replace in-vivo experiments. As said before in-vivo experiments were hampered by the
availability of reliable aerosol generators, as well as particle counting and -sizing tech-
niques. At the moment these became available, nothing inhibited in-vivo experiments.
The design of the experiments was (and still is) heavily influenced by the state of the art
of aerosol generators and measuring equipment. As result, one can see that the first
experiments were confined to measurement of the total deposition. One measured the
number of inhaled and exhaled number of particles, the difference being the number
deposited. It is clear that data on the regional deposition can not be derived from these
experiments. The g-camera and radioactive labelled particles were needed to generate
those data.
In this chapter the emphasis is on the deposition of non-therapeutic aerosols.
Deposition in healthy volunteers
Wilson was one of the firsts to measure the alveolar deposition in healthy volunteers.
Using a so called Sinclair-L Mer generator he administered insoluble particles containing
a nucleus of Na24Cl, ranging from 0.2 mm to ±3 mm. The particles deposited in the alveoli
will not be cleared within 24 hours and the radioactivity measured after 24 hours there-
fore represents the alveolar deposition. The alveolar deposition showed a bimodal
distribution in almost all volunteers around 0.4 mm and 1 mm, not anticipated by the
model studies reviewed in the previous chapter1. Three years later Landahl administered
0.11 mm to 6.3 mm particles and measured the difference between the in- and exhaled
number of particles, as function of the inhaled volume. The results, presented in Table
1, are better in line with theoretical predictions: a deposition minimum is observed around
0.5 mm and increasing volumes of inhaled air cause additional deposition2. Landahl
2compared these experimental data to his theoretical predictions and concluded that the
experimental depositi n for 1 mm particles was 'too low'3.
inhalation mode (flow and volume)
particle size (mm)
300 ml/s, 450 ml300 ml/s, 900 ml300 ml/s, 1350 ml
0.11 34 36 46
0.25 32 32 41
0.55 17 23 33
1.4 26 53 65
2.9 52 69 82
3.8 59 72 89
6.3 86 93 96
Table 1 In-vivo percentual total deposition according to Landahl2
Lippmann and Albert measured the total deposition (=trache bronchial plus alveolar) of
radioactive 2.1 µm to 12.5 µm iron oxide particles immediately after administration. As
known, these iron oxide particles are cleared from the tracheobronchial compartment by
mucocilairy transport within 24 hours, so the alveolar deposition equals the radioactive
count after 24 hours. The difference between the two measurements being the tracheo-
bronchial deposition4. Their results indicate that the alveolar deposition decreases rapidly
with particles >5 mm, while the tracheobronchial deposition related to the so-called
impaction parameter s(dm)2Qavg (s=density, dm= diameter and Qavg= average inhalation
flow). This indicates that the tracheobronchial deposition is governed by impaction and
not by sedimentation.
Foord used the same technique to measure total and alveolar deposition, the result  are
presented in Table 25. Foord also found a relationship between dm2 and the tracheobron-
chial deposition, thereby strengthening the findings of L ppmann.
particle size (mm)
Site of deposition
2.5 5 7.5
3exhaled 31 14 5
mouth/pharynx 5 17 40
tracheobronchial 10 24 39
alveolar 54 45 16
Table 2 Percentual deposition, according to Foord, of increasing particle sizes,
broken down by site1
One of the main issues of the group of Heyder was a tight control of the inhalation
manoeuvre: they changed the flow, keeping the volume constant or the volume, keeping
the flow constant6. In general it was found that the deposition increases with larger
inhalation volumes. An example: an increase of the inhaled volume from 250 ml to 2000
ml (flow 250 ml/s) causes 30% of all 0.5 mm particles to deposit in stead of 5%, while
the deposition of 3 mm particles increases from 25% to 85%. The explanation offered is
that these particles mainly deposit by sedimentation, the larger particles of course to a
higher extent than the smaller ones. The increase in inhaled volume actually means an
increase in residence time, favouring deposition. Contrary, an increase in inhalation flow
leads to a decrease in deposition, because residence time reduces. So changing flow and
volume in such a way that residence time is kept constant, would not change the deposi-
tion. In Table 3 the results of this experiment are presented, showing the validity of this
thought. It means that the principal deposition mechanism for particles <3 mm is sedi-
mentation, inertial impaction plays a less important role.
Particle size (µm)Inhaled vol-
ume (ml)
Flow (ml/s) Residence
time (s) 0.2 0.62 1 2 3
250 250 2 8 6 7 13 21
1000 1000 2 8 7 8 24 44
500 250 2 14 11 14 27 42
1000 500 2 14 11 15 34 58
1000 250 4 33 25 40 69 79
2000 500 4 34 29 44 75 82
4Table 3 Deposition as function of particle size, inhaled volume and breathing
frequency as determined by He der1. The residence time comprises the inhalation and exha-
lation and is calculated as volume divided by flow multiplied by two.
In a next experiment the group used the technique described above f immediate and 24
hours measurements of the radioactive count after administering insoluble radioactive
aerosols to estimate the total, tracheobronchial and alveolar deposition. Again, one
controlled the inhalation manoeuvre tightly and the results clearly indicate that the
alveolar deposition (by sedimentation) of the smaller particles is very high7. For particles
<2 mm the total and alveolar deposition are the same. Extrathoracic and tracheobronchial
deposition of the larger particles were governed by inertial deposition, because a good
correlation between the impaction parameter and the deposition existed, confirming the
results of Lippmann4. Years later an extension of these investigations was published: the
total and regional deposition of a larger range of particles became known (Fig. 1)8.
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Fig. 1 In-vivo deposition of particles in the human airways8.
(flow rate : 250 ml/s, tidal volume: 1000 ml)
In another experiment by the same group, one was able to prove that the total deposition
is strongly governed by the aerodynamic particle size. Two types of aerosols were
5administered: sebacate and iron oxide. Sebacate has a lower density than iron oxide and
23% of the 1 mm sebacate particles deposited compared to 50% of the heavier iron oxide
particles. The aerodynamic particle size of iron oxide is by definition larger and when one
corrected the deposition for these differences, the differences in deposition disappeared
completely. Similar 'corrections' for the flow or residence time were calculated and the
group was able to construct a so-called deposition parameter (Xm). This parameter
normalises the total deposition in terms of particle size, particle density, resid nc  time
and inhalation flow. In other words, besides particle size, particle density, residence time
and inhalation flow, there are no other factors governing total deposition9.
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in which:d= particle diameter (mm), d0= 1 mm,
r= particle density (g/cm3), r0= 1 g/cm3
V= inhalation flow (cm3/s), V0= 1 cm3/s
F= breathing frequency (min-1), F0= 1 min-1
The variability of the deposition in healthy volunteers
In most in-vivo experiments a considerable inter/intrai dividual variability was noted.
Tarroni tried to explain the variability by instructing volunteers to inhale 0.6 mm partic s
starting from different lung volumes, while keeping the vital capacity constant. He noted
that lower starting volumes lead to an increased deposition10. D creased airway dimen-
sions at lower lung volumes no doubt caused this phenomenon.
Stahlhofen, using in-vivo deposition data and some deposition equations, was able to
calculate the average airway diameter11. The results of these calculations point at a
diameter coefficient of variation of approx. 23%, which according to Stahlhofen is
caused by differences in extrathoracic deposition. His theory is based on the fact that a
high extrathoracic deposition logically must result in a low airway deposition. So vari-
ability in the extrathoracic deposition causes highly different amounts of particles to
penetrate into the lower airways. This theory was confirmed by two experiments of
Svartengren, who found in two experiments that the mouth and throat deposition of 3.6
6mm particles in asthmatics ranged from 7-66% resp. 9-76% of the dose administered12
13. Heyder compared the variance of the total deposition using controlled and spontane-
ous breathing cycli14. He noted that the intraindividual variability was small, when the
breathing cycle was controlled tightly. A second finding was a smaller interindividual
variability after controlled compared to uncontrolled breathing. This lead Heyder to
conclude that variability is caused by morphological and physiological factors. Control-
ling the breathing cycle eliminates the physiological factor and the interindividual vari-
ability left is due to the differences in airway anatomy. In later years Benn t also noted
that the interindividual coefficient of variation of the alveolar d position increased from
6% to 13% after switching from controlled to uncontrolled breathing15.
Yeates and Svartengren, who both discovered a significant correlation between decreas-
ing FEV1, MMFR and MEF25 and a decreased deposition in the alveoli, substantiated the
importance of morphological factors16 17. Agnew, howev r, was unable to find such
correlation: in his experiment only inhalation flow correlated inversely to the alveolar
deposition. The volunteers, however, showed a small range of FEV1's, making it harder
to find a correlation18. Svartengren further examined the relation between airway mor-
phology and deposition. He administered 4 mm Teflon particles, containing a radioactive
label before and after m tacholine-induced bronchoconstricti in healthy volunteers.
The airway resistance increased from 1.2 to 2.8 cm H2O/l/s and at the same time the
alveolar deposition decreased by 81%19. Repeating the experiment, but also measuring
the deposition in the trachea showed that after bronchoconstriction the alveolar deposi-
tion decreased, while tracheal deposition increased20.
Deposition in asthmatic patients
These kind of deposition experiments were soon extended to asthmatic patients, but from
the start a different set up was chosen: many researchers administered radiolabelled
particles of a small size range or only one size and visualised the deposition pattern of the
particles by means of g-cameras.
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Fig. 2 Total airway deposition of non-hygroscopic particles in healthy and
asthmatic subjects22
Only a few experiments were published in which the total deposition of a range of
particle sizes was measured in the classic way, that is counting the difference between in-
and exhaled number of particles. Anderson asked 5 asthmatic volunteers (mean FEV1
40% of predicted) to inhale NaCl-particles in the range of 0.02 to 0.24 mm and compared
the airway deposition to normal subjects. The results indicate that the deposition in
asthmatics is increased. Anderson concluded that this is partly due to the constrictions
of the airways, but also due to the longer residence time of particles in the asthmatic
airways. The asthmatic volunteers were said to breath slower than the healthy volun-
teers21. Schiller-Scotland measured the total deposition of 1-3 µm particles in healthy and
asthmatic volunteers. The results are shown in Fig. 2 and it is clear that differences in the
deposition are almost nil as particle sizes equalled 3 µm (inspiratory flow 250 ml/sec, no
breath holding). A second finding was that the deposition of 1 µm particles was inversely
correlated to the FEV1/IVC ratio and to the MEF50 values. These correlation’s could not
be demonstrated for the larger particles. Breath holding proved to be highly important,
because the differences depicted in Fig. 2 disappeared when breath holding was changed
to 6 sec, the increase in residence time being responsible for this effect22.
8Ramanna, using the g-camera technique, visually scored g- amera images of 70 volun-
teers, either healthy or asthmatic. He noticed that the 'asthmatic images' were character-
ised by a spotty and/or centrally orientated deposition. In a number of asthmatic volun-
teers these abnormal findings were present despite normal lung function tests. Ramanna
interpreted this as a higher sensitivity of the aerosol penetration to small changes of the
airway-anatomy compared standard lung function testing23. Li , Taplin, and Santolican-
dro confirmed these observations24 25 26.
Dolovich attempted to quantify the g-cam ra images by counting the radioactivity in two
areas: a central and peripheral one. The ratio of the central over the peripheral activity
(C/P-ratio) bears a relation to the penetration of particles: a high ratio indicates a low
penetration27. In a small group of patients with an average FEV1 32.5% of predicted,
Smaldone found that the mean C/P-ratio (for 1.5 mm particles) was 1.98 compared to
1.02 in healthy volunteers28. Chung and co-workers used this technique to demonstrate
that a linear relationship between the conductance of the airways and the C/P ratio exists
in asthmatics (r=0.69, p=0.001), while the changes due to dilation by salbutamol in the
conductance and C/P ratio were also related (r=0.68, p<0.001)29. A disadvantage of the
'Dolovich-method' is that no rule exists how to define the central and peripheral fields in
the scan and mostly it is done subjectively. This can bias researchers and several attempts
were made to exclude this subjective element. Pavia scanned the thorax from the central
to peripheral fields. By doing so he obtained a curve relating the distance from the
midline and the intensity30. Laube scored the intensity of every pixel (= the smallest
picture element) in the scan and constructed a frequency histogram. The more atypical
the distribution of the aerosol is, the greater the deviation from the normal distribution
will be and the histogram will show skewness and kurtosis. In asthmatic patients both
parameters are highly significant, indicating strong deviations from the normal distribu-
tion. A relation between baseline FEV1 and the degree of skewness/kurtosis was shown
by Laube (confirmed by Olseni) and in cystic fibrosis patients31 32 33.
9Literature
                                         
1 Wilson I.B. and LaMer V.K.
The retention of aerosol particles in the human respiratory tract as a function of particle radius.
J Ind Hyg Tox 30: 265-280 1948.
2 Landahl H.D., Tracewell T.N. and Lassen W.H.
On the retention of air-borne particulates in the human lung.
Ind Hyg Occ Med ??: 359-366 1951.
3 Landahl H.D.
On the removal of airborne droplets by the human respiratory tract: I. The lung.
Bull Math Biophys 12: 43-56 1950.
4 Lippmann M. and Albert R.E.
The effect of particle size on the regional deposition of inhaled aerosols in the human respiratory tract.
Am Ind Hyg Ass J 30: 257-275 1969.
5 Foord N., Black A. and Walsh M.
Pulmonary deposition of inhaled particles with diameters in the range 2.5 to 7.5 µm
In: Inhaled particles IV
Ed: Walton W.H.
Pergamon Press, Oxford, 1975
6 Heyder J., Armbuster L., Gebhart J., Grein E. and Stahlhofen W.
Total deposition of aerosol particles in the human respiratory tract for nose and mouth breathing.
J Aerosol Sci 6: 311-328 1975.
7 Stahlhofen W. Gebhart J. and Heyder J.
Experimental determination of the regional deposition of aerosol particles in the human respiratory tract.
Am Ind Hyg Ass J 41: 385-398 1980.
8 Heyder J., Gebhart J., Rudolf G., Schiller C.F. and Stahlhofen W.
Deposition of particles in the human respiratory tract in the size range 0.005-15 mm.
J Aerosol Sci 17: 811-825 1986.
9 Heyder J., Gebhart J., Rudolf G. and Stahlhofen W.
Physical factors determining particle deposition in the human respiratory tract.
J Aerosol Sci 11: 505-551 1980.
10 Tarroni G., Melandri C., Prodi V., De Zaiacomo T., Formignani M. and Bassi P.
An indication on the biological variability of aerosol total deposition in humans.
Am Ind Hyg Assoc J 41: 826-831 1980.
11 Stahlhofen W., Gebhart J. and Heyder J.
Biological variability of regional deposition of aerosol particles in the human respiratory tr ct.
Am Ind Hyg Assoc J 42: 348-353 1981.
12 Svartengren M., Anderson M., Bylin G., Philipson K. and Camner P.
Mouth and throat deposition of 3.6 mm radiolabelled particles in asthmatics.
J Aerosol Med 4: 313-321 1991.
13 Svartengren K., Lindestad P-Å, Svartengren M., Bylin G., Philipson K. and Camner P.
Deposition of inhaled particles in the mouth and throat of asthmatic subjects,
10
                                                                                                            
Eur Respir J 7: 1467-1473 1994.
14 Heyder J., Gebhart J., Stahlhofen W. and Stuck B.
Biological variability of particle deposition in the human respiratory tract during controlled and spontaneous
mouth-breathing.
Ann Occup Hyg 26: 137-147 1982.
15 Bennet W.D. and Smaldone G.C.
Human variation in the peripheral air-space deposition of inhaled particles.
J Appl Physiol 62: 1603-1610 1987.
16 Yeates D.B., Gerrity T.R. and Garrard S.
Characteristics of tracheobronchial deposition and clearance in man.
Ann Occup Hyg 26: 245-257 1982.
17 Svartengren M., Hassler E., Philipson K. and Camner P.
Spirometric data and penetration of particles to the alveoli.
Br J Ind Med 43: 188-191 1986.
18 Agnew J.E., Pavia P. and Clarke S.W.
Factors affecting the alveolar deposition of 5 Fm inhaled particles in healthy subject .
Clin Phys Physiol Meas 6: 27-36 1985.
19 Svartengren M., Philipson K., Linnman L. and Camner P.
Airway resistance and deposition of particles in the lung.
Exp Lung Res 7: 257-269 1984.
20 Svartengren M., Philipson K., Linnman L. and Camner P.
Regional deposition in human lung of 2.5 µm particles.
Exp Lung Res 12: 265-279 1987.
21 Anderson P.J., Wilson D.J. and Hiller F.C.
Respiratory tract deposition of ultrafine particles in subjects with obstructive or restrictive lung disease.
Chest 97: 1115-1120 1990.
22 Schiller-Scotland C.F., Gebhart J., Hochrainer D. and Siekmeier R.
Deposition of inspired aerosol particles within the respiratory tract of patients with obstructive lung disease
Toxicology Letters 88: 255-261 1996.
23 Ramanna L., Tashkin D.P., Taplin G.V., Elam D., etels R., Coulson A. and Rokaw S.N.
Radioaerosol lung imaging in chronic obstructive pulmonary disease. Comparison with pulmonary function
tests and roentgenography.
Chest 68: 634-640 1975.
24 Lin M.S. and Goodwin D.A.
Pulmonary distribution of an inhaled radioaerosol in obstructive pulmonary disease.
Radiology 118: 645-651 1976.
25 Taplin G.V., Tashkin D.P., Chopra S.K., Anselmi O.E., Elam D., Calvarese B., Coulson A., Detels
R. and Rokaw S.N.
Early detection of chronic obstructive pulmonary disease using radionucl delungimaging procedures.
Chest 71: 567-575 1977.
26 Santolicandro A. and Giuntini C.
Patterns of deposition of labelled monodisperse aerosols in obstructive lung disease.
11
                                                                                                            
J Nucl Med 23: 115-127 1979.
27 Dolovich M.B., Sanchis J., Rossman C. and Newhouse M.T.
Aerosol penetrance: a sensitive index of peripheral airways obstruction.
J Appl Phys 40: 468-471 1976.
28 Smaldone G.C. and Messina M.S.
Flow limitation, cough and patterns of aerosol deposition in humans.
J Appl Physiol 59: 515-520 1985.
29 Chung K.F., Jeyasingh K. and Snashall P.D.
Influence of airway calibre on the intrapulmonary dose and distribution of inhaled aerosol in normal and
asthmatic subjects.
Eur J Respir 1: 890-895 1988.
30 Pavia D., Thomson M. and Shannon H.S.
Aerosol inhalation and depth of deposition in the human lung.
Arch Environ Health 32: 131-136 1977.
31 Laube B.L., Limks J.M., Wagner H.N., Norman P.S., Koller D.W., LaFrance N.D. and Adams G.K.
Simplified assessment of fine aerosol distribution in human airways.
J Nucl Med 29: 1057-1065 1988.
32 Olseni L., Palmer J. and Wollmer P.
Quantitative evaluation of aerosol deposition patterns in the lung in patients with chronic bronchitis.
Physiol Meas 15: 41-48 1994.
33 Laube B.L., Limks J.M., LaFrance N.D., Wagner H.N., and Rosenstein B.J.
Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis
patients.
Chest 95: 822-830 1989.
1The deposition of therapeutic aerosols
Introduction
The character and way of administration of therapeutic aerosols differs profoundly
from the non-therapeutic aerosols described above. Most ‘non-therapeutic’ experi-
ments were performed with non-ygroscopic particles, while aerosols were inhaled
from still air. Therapeutic aerosols frequently contain hygroscopic drugs and are not
delivered from still air. Therefore, the deposition characteristics of therapeutic sys-
tems can (and will) differ heavily and is reviewed below, with special emphasis on
the influence of the formulation on the deposition. Subsequently the relation between
particle size distribution and therapeutic effect is discussed.
Deposition of metered dose inhalers
Numerous experiments have been carried out to determine the deposition efficacy of
the metered dose inhaler (MDI) by measuring the percentual deposition. Although
from study to study, the outcome varies somewhat, overall results indicate that a
small amount of the dose emitted actually enters the lungs. Most experiments report
that 10-20% of the dose delivered, ends up in the airways and alveoli1 2 3 4. The ra-
sons for this inefficacy lies in the way patients use MDI’s and in the formulation.
Aerosols generated by MDI’s are characterised by large primary droplets showing
high velocities. Early measurements of the droplet sizes indicate a MMAD of 2.8-4.3
mm, depending on the brand tested5. The aerosols measured, however, resided in a
flask for 1 to 4 min before measurement, so the results indicate the size after evapo-
ration of the liquid propellants: the primary size must have been larger. Later,
slightly larger sizes (MMAD 2.3 to 8.3 mm) were reported, but again these aerosols
were dried before measurement6. The initial droplet size of a MDI aerosol is said to
be approximately 30 mm and the droplets leave the inhaler with high speeds (±120
km/h)7. These circumstances make it very likely that the majority of the droplets im-
pact in the oropharynx, because there is not sufficient time for evaporation. The re-
sult is only 10-20% effective deposition in the lower airways.
2Decreasing the primary droplet size seems to be the logical solution. Unfortunately,
this can only be achieved by increasing the pressure in the canister of the MDI. By
increasing the canister-pressure from 374 kPa to 502 kPa,  Morén w s able to de-
crease the mouth deposition from 12.7% to 8.3%. This effect was, however, only
noticeable at a low metered volume, which is equivalent to a low emitted dose. In-
creasing the metered volume increased the mouth deposition, despite the pressure
used8. In later experiments, using technetium labelled aerosols, it was found that a
high pressure MDI delivered 17.6% of the dose to the airways and alveoli, compared
to 13.6% of the low-pressure inhaler. The oropharyngeal deposition decreased by a
small 3.9% to 72.8%9. The advantages of a reduced primary droplet size seem to be
minimal: the higher pressure necessary increases the inertia of the droplets and this
factor counterbalances the beneficial effects of size reduction.
A remark has to be made: the results above were obtained by using so called suspen-
sion aerosols. The drug crystals in these aerosols do not dissolve in the propellants,
but form a suspension. This means that in a primary droplet several crystals will be
included, so the secondary size is dependent on the number (and size) of the crystals
present in the primary droplet. The gain of reducing the primary droplet is therefore
on forehand limited. If one dissolves the drug in the propellants one can avoid the
above mentioned problems: experiments, using a model drug, showed that a lung
deposition of 39% is achievable with propellant soluble drugs. Improving the ad-
ministration using a spacer further increased the lung deposition to 57%10. Again, as
with suspension MDI’s, an increase in canister pressure (from 255 kPa to 488 kPa)
causes smaller primary droplets and an increase in lung deposition (from 50.9% to
65%)11. Only few drugs are dissolvable in the propellants.
spacers
An effective way to improve drug delivery from MDI’s is to slow down the high
initial droplet speed and to remove any liquid propellant by evaporation. This can be
achieved by firing the aerosol into a temporary container, a spacer device. Currently
many of these devices are available and although based on the same principle it h s
become clear that different brands of spacers can elicit a profound change in the
aerosol cloud characteristics.
3Dolovich reported that a small holding chamber lowered the ropharyngeal deposi-
tion from 71% of the emitted dose to 4%, while the total lung deposition remained
unaltered. The deposition pattern, however, changed to a more peripheral profile:
25% of the total lung mass was recovered from the outer lung zone following the
MDI compared to 34% of the combination12. Newman reported the same for another
spacer device, the oropharyngeal deposition decreased form 81% to 17% and the
lung deposition increased form 8.7% to 21%. In the spacer 56% of the emitted dose
deposited13. These data illustrate the general character of spacers: a considerable
amount of drug deposits within the spacer itself and that mass is of course not avail-
able for inhalation. Judging from the lowered oropharyngeal deposition, the retained
mass must consist of large particles. In this way a spacer acts as a separating device
taking out the bulk of the large particles, while offering sufficient evaporation time
for smaller droplets. These droplets will decrease in size, enabling them to enter the
lower airways in higher numbers.
That separating action of spacers is related to their construction. Vidgren showed that
the spacer deposition can vary enormously between different brands. A sodium cro-
moglycate MDI elicited an oropharyngeal deposition of 81%, lowered to 56% by a
spacer called Inhalet® and to 22% by an Inspirease®. The lung deposition ranged
from between 16% to 20%14. Many others confirmed these data. Holzner reported
that the dose deposited in the spacer depends on the spacer design, but also the MDI
brand (see Table 1). It therefore seems hard to predict the characteristics of a spacer-
MDI combination15.
Spacer Metered dose inhaler AMetered dose inhaler B
Inhacort (telescope) 29 25.4
Inhacort (normal) 40.2 29.2
Viarox 37.9 19.3
Aru 35.7 37.5
Rondo 48.6 35.9
Fisonair 44.5 31.8
Nebulator 66.6 61.5
Beclomet 83.6 74.4
4Spacer Metered dose inhaler AMetered dose inhaler B
Volumatic 77 71.9
Table 1 Percentage of the emitted dose retained in  the spacer of several spacer-
MDI combinations15
Barry and O’Callaghan reported an identical ‘unpredictable’ behaviour of several
combinations16, 17. It is no surprise that Hindle subsequently showed that the systemi-
cally absorbed amount of salbutamol highly differed between several combinations:
the total 24h salbutamol urinary recovery varied between 44% of the emitted dose
and 27%18. Later on it was shown that the mass output of spacers is negatively influ-
enced by electrostatic charges or by multiple act ations19. Removing the electrostatic
charges increased the mass of drug delivered to the lungs20.
The conclusion of ‘unpredictablility’ can also be drawn with respect to the particle
size distribution. In the same experiment Holzner also measured the aerosol mass
consisting of particles <6.4 µm (Table 2)15.
Spacer Metered dose inhaler AMetered dose inhaler B
Inhacort (telescope) 26.6 36.5
Inhacort (normal) 26 32.1
Viarox 27 41.7
Aru 29 25.2
Rondo 25.5 32.7
Fisonair 23.9 27.6
Nebulator 16.8 21.4
Beclomet 4.2 6.7
Volumatic 4.4 8.3
Table 2 Percentual particle mass <6.4 µm inhaled from several MDI-spacer
combinations15
Similar findings have been reported by others, all showing widely different aerosol
particle size distributions16 17 21. The reason for these differences mostly remains un-
explained. Some blame the design of an exhalation valve in the spacer (they too
5much act as an impactor for inhaled particles), while others stress the electrostatic
properties. More work needs to be done to elucidate this problem.
The conclusion is that, in general, a spacer improves the deposition characteristics of
a MDI-aerosol cloud from by removing large particles, but the extent of this removal
depends on many (unknown) factors. Interchangeability of spacers is an issue not
solved.
Dry powder inhalers
Dry powder inhalers lack the hand/lung co-ordination problems of MDI’s and are
easier to use. The powder formulation comprises frequently a blend of lactose and
micronised drug. The lactose acts as a bulking agent, while it prevents the mic onised
drug from agglomeration. During inhalation the inspired air aerosolises the blend and
turbulent air separates the drug crystals from the lactose. Inhalers do exist, which
contain lactose free formulations, but even with these a separation process is present,
rendering them not basically different from lactose based inhalers. The efficacy in
terms of lung deposition depends on several factors, like the drug itself, the design of
the inhaler, the height of the inspiratory flow22. In the following paragraphs the ef-
fects of some of these factors will be discussed.
Inhaler design
Dry powder inhalers (DPI) are generally believed to show lower deposition percent-
ages as MDI’s. Melchor radiolabelled salbutamol raw material and incorporated it
into both a MDI and a DPI, subsequently measuring the total lung deposition as per-
centage of the nominal dose.  In healthy volunteers 22% of the MDI dose was recov-
ered form the lungs opposed to 12.5% of the DPI dose, in asthmatics these figures
were, respectively, 18.2% and 11.4%4. Others found similar results23. The actual
deposition is, however, highly dependent on the DPI itself: comparing the deposition
of a Turbuhaler with that of a MDI lead Thorsson to conclude that the Turbuhaler’s
deposition was twice as high. They measured the systemic uptake of budesonid a ter
a Turbuhaler of MDI and reported a systemic availability of 32% for the Turbuhaler
and 15% for the MDI24. Later this was also shown for a terbutaline Turbuhaler25.
However, one has to remember that measuring the systemic availability does not
necessarily reflect the total deposition of drug in the lung: part of the drug mass
6might not be absorbed. This is most likely to occur in the upper airways where mu-
cociliary transport is fast and the mucosa relatively thick. So absorption might be
dependent on the deposition pattern. The latter would have been measured by scintig-
raphy.
Vigdren manufactured a radiolabelled sodium cromoglycate/lactose blend and this
‘standard’ formulation was inhaled through four inhalers (Spinhaler®, ISF®, Ingel-
heim® and Rotahaler®). The deposition within the (healthy) lungs differed considera-
bly: 16.4% of the dose after the ISF-inhaler® compared to 6.2% after the Rotahaler26.
The reason given for this large difference is the (in)efficacy to aerosolise the drug.
When powder is insufficiently aerosolised, it will be retained in the inhaler. The di-
rect effect being a low dose delivered to the patient and too much drug/lactose com-
plexes too large to penetrate into the airways.
Inhalation flow
The powder in a DPI is to be aerosolised by the air inhaled by the patient and intui-
tively the more air inhaled the better the aerosolisation. The latter indicates that the
aerosol created is effort-dependent and much research has gone into this area. A pos-
sible approach is to measure the resistance of the inhaler and peak inspiratory flow
through that inhaler. This approach is based on the assumption that to obtain a good
dispersion of the powder, a minimum amount of air at a minimum flow must be in-
haled through the DPI. Should a patient not be able to meet these requirements, he or
she should use another and more suitable DPI. Clark has determined the resistance of
several DPI’s and the data are depicted in Table 327.
Device Resistance (cm H2O1/2/l/min)
Rotahaler® 0.040
Spinhaler® 0.051
ISF inhaler® 0.055
Diskhaler® 0.067
Turbuhaler® 0.100
Inhalator Boehringer Ingelheim® 0.180
Table 3 Resistance of six commercial inhalers27
7They also measured the maximum pressure drop over the inhaler volunteers could
generate and noted that, even at maximum effort, a maximum pressure-drop when
the inhaler resistance was larger than 0.1 cm H2O/(l/min). Apparently the diaphragm
and intercostal muscles strength limits the pressure drop over the inhaler one can
generate. Later Ross showed that an increase of the flow through an inhaler is
equivalent with a reduction of the MMAD and an increase of the mass < 5µm28. A
relation between a low inspiratory flow, dispersion and suboptimal clinical effects is
apparent.
Engel, who taught patients to inhale at increasing flows through a Turbuhaler, inves-
tigated the clinical effect of these varying characteristics29. Th  highest flow was 84
l/min, releasing 86% of a 5 mg terbutaline dose, the lowest flow 34 l/min resulting in
inhaling 58% of the same dose. No significant differences in bronchodilation were
found, nor were they present with respect to side effects. Zanen et al found the same
when testing the ISF inhaler with a salbutamol/lactose blend at 40 l/min or 80 l/min30.
The drug itself, however, is of importance: Bisgaard showed inhalation flow depend-
ence when testing the same ISF device but now with formoterol31.
The conclusion of all data above is that the characteristics of the aerosol cloud from a
DPI are highly dependent on the inhaler itself and no general statements are possible.
The effects of particle size distribution on the clinical effect
From the earlier chapters it is clear that size has a profound effect on the penetration
of particles into the lower airways. It is logical to expect that the degree of penetra-
tion and deposition patterns of therapeutic aerosols influences the beneficial effects
of an inhaled drug. In the sections below the relationship between size and clinical
effect is elucidated.
Bronchodilators and sodium cromoglycate
The first report, linking the effect of an aerosol to particle size distribution, comes
from Godfrey. Using a spinning disc nebuliser he generated 2 µm and 11.7 µm so-
dium cromoglycate particles, in both cases approximately 30 mg of drug were in-
haled. Subsequent exercise testing showed that the therapeutic effect of the 11.7 µm
aerosol was not significantly different from placebo, only the smaller 2 µm aerosol
was effective in reducing EIB. The probable explanation for this finding is that 11.7
8µm particles of a highly hygroscopic drug will grow into very large droplets in the
humid airways, so it can be doubted whether these particles ever reached the lower
airways in an effective quantity. It appears that two placebo’s were compared to one
‘active’ preparation32. Later Ruffin administered 3.3 µm and 1.5 µm isoproterenol
aerosols and noted that the cumulative dose-response curve of the 1.5 µm aerosol
was shifted to the right, indicating a lower potency. Whether this shift was signifi-
cant, is not mentioned, however33.
Rees milled terbutaline crystals down to three different size ranges. The mass median
diameters were 5.6 µm, 9.1 µm and 13.6 µm respectively, but the distribution
showed strong polydispersity with considerable overlap. These crystal sizes were
incorporated into standard MDI’s and it was shown that only the smallest aerosol
improved the FEV1, sGaw and MEF50 significantly. The two remaining aerosols had
no dilating effect at all and the investigators concluded that effective particles should
be smaller than 5 µm34. Using three different nebulisers, Clay generated terbutaline
aerosols with a mass median diameter of 1.8 µm, 4.6 µm and 10.3 µm. All aerosols
elicited significant changes with respect to baseline. Except in case of the MEF50/25,
where the smallest aerosol was most potent, none of the aerosols differed signifi-
cantly amongst each other35. A year later Clay showed that 80% of the 1.8 µm aero-
sol deposited in the lung compared to 60% and 44% of the 4.6 µm and 10.3 µm aero-
sols36.
Again using different types of nebulisers, Mitchell generated 1.4 µm and 5.5 µm
salbutamol aerosols. The lung deposition was studied by radiolabelling and no sig-
nificant difference was found between the deposition patterns. Mitchell constructed
cumulative dose-FEV1 curves and these curves showed to be superimposable37.
These conclusions, which are only based on the FEV1-improvement, are in line with
those of Clay, t.i. no clear cut relationship between particle size distribution and
clinical efficacy.
The data above suggest that the clinical effect of bronchodilator aerosols is not
strongly influenced by the size distribution, but some evidence emerged that particles
below 5 µm are more potent. The importance of that mass <5 µm was shown by
Persson, who modified the mouthpiece of terbutaline Turbuhal rs in such a way that
the inhalers delivered either 90 µg, 40 µg or 5 µg as <5 µm particles. The increase in
9FEV1 with the 5 µg mouthpiece was significantly lower than with the higher dose
mouthpieces. The latter two did not differ from each other38.
Johnson reported that 3.3 µm particles were more potent than 7.7 µm particles39. Two
different nebulisers generated these particles and both for ipratropium bromide and
salbutamol cumulative dose-response curves were constructed. The ipratropium
curves were not significantly different for all lung function parameters measured,
while the salbutamol curves did show a higher potency for the smallest aerosol. Ra-
diolabelling studies did not show significant changes in deposition patterns of the
aerosols, but a higher total lung dose of smaller aerosol. This indicates that the oro-
pharyngeal passage of the 3.3 µm aerosol is better, which is apparently the explana-
tion for the higher potency. Patel and co-workers used a spinning top generator to
manufacture monodisperse 2.5 µm and 5 µm isoproterenol aerosols40. The advantage
of this approach is that it has an higher discriminative power: nebuliser aerosols do
generate highly polydisperse aerosols and the overlap in the particle size distributions
tend to obscure differences in size-effects. The 2.5 µm dose-response curves of Patel
for all parameters measured were shifted to the left, indicating a higher potency. He
calculated that on a weight basis the 2.5 µm aerosol was 2 to 4 times more potent
compared to the 5 µm aerosol. This conclusion is however questionable because one
did not control the inhaled dosage accurately.
The parallel designed study by Hultquist comparing 1.5 µm and 4.8 µm particles
generated by two different nebulisers could not show an advantage for the smaller
aerosol41. Neither the cumulative FEV1 dose response curves, nor parameters for gas-
exchange did show significant differences.
Histamine/methacholine
Only a few experiments relating particle size and histamine/methacholine efficacy
have been performed. Ruffin administrated 1.5 µm or 3 µm methacholine aerosols by
means of two nebulisers. Like the bronchodilator experiments, Ruffin noted a con-
siderable right shift of the 1.5 µm dose-response curves. He calculated that the aver-
age potency-ratio was approx. 15:1 in favour of the 3 µm aerosol42. Contrary to these
findings, Ryan could not find any influence of the particle size distribution43. He
compared 1.32 µm and 3.6 µm methacholine aerosols using (as usual) different
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nebulisers and corrected for differences in the mass output of the nebulisers. He
noted that the weight loss per minute per nebuliser differed and that the ratio of the
PC20 and the mass output per minute was very similar. Based on that observation he
concluded that nebuliser mass output is highly important, whereas particle is size not.
To complicate interpretation, Laube could show that a central deposition of metha-
choline was equivalent to lower PD20-values44. She used only one type of nebuliser,
but asked volunteers to inhale at high flows (60 l/min) to induce a central deposition
pattern or at low (12 l/min) flows for a more peripheral pattern. The first was
equivalent with a significantly lower PD20: log PD20 0.77 versus 1.20. This prefer-
ence for a central methacholine distribution was confirmed by Sch ekel et al. by
comparing a 2 µm and 9 µm aerosol45.
Next to the above experiments into the aerosol size and histamine/met acholi  rela-
tionship, several researchers tried to explain the interindividual variability of the re-
sponsiveness to inhaled histamine/methacholine by correlating it to the inhaled dose
of these drugs. Donna concluded that in a group of 10 healthy volunteers and asth-
matics that differences in methacholine responsiveness are not due to different
masses inhaled from the nebuliser, but to the variability of the intrinsic abnormality46.
One also concluded that, in healthy volunteers, the degree of bronchoconstriction is
correlated to the inhaled dose, which was not found in asthmatics. This can be ex-
pected to a certain extent. Any correlation between inhaled dose and responsiveness
will disappear as the int rindividual variability of the latter increases. The geometric
SD of the methacholine responsiveness was 6.7 in the asthmatic group and 2.6 in the
healthy volunteers. This alone makes it hard to find significant correlatio s in such
small samples.
Gillet, too, was unable to discover a correlation between inhaled dose and methach-
line responsiveness much for the same reason as above47. However, one did find a
significant correlation between the inhaled atropine dose and the elicited decrease of
the methacholine responsiveness. Atropine is a methacholine antagonist, so the
higher the dose deposited, the stronger the antagonism: a correlation between atro-
pine dose and methacholine responsiveness seems logical. Anderson again noted that
the interindividual methacholine responsiveness variability exceeded that of the aero-
sol deposition, so deposition variability can not explain it48.
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Aim of the study
The data on a relationship between particle size and clinical efficacy, as reviewed in
the previous chapter, are hard to interpret. Results of bronchodilators studies are
contradictory: early trials suggest that particles simply should be smaller than 5 µm
and that the actual particle size below that 5 µm is irrelevant1 2 3. Other researchers,
however, do show differences in the degree of bronchodilation in the <5 µm size
range4 5 6. Unfortunately, an optimal particle size for a bronchodilator aerosol cloud
can not be derived from the latter experiments. Frequently one compared just two
particle sizes and amongst the studies the range of sizes varied.
The contradictions on the importance of the below 5 µm size may find their origin in
the experimental set up of the studies. Most experiments show a common funda-
mental weakness: in order to generate the aerosols, one uses different nebulisers. The
nebulisers generate smaller of larger polydisperse aerosols, which renders it hard to
define the effect of a changing particle size due to the considerable overlap in size
distributions7 8. The stronger that overlap, the lower the chance to find a particle size
effect. So, whether one reports a significant size/efficacy relationship or not, seems
to be nebuliser dependent. Studies, using nebulisers with narrow particle size distri-
butions, have the highest probability is to find a particle size efficacy relationship.
Information on that distribution is lacking in the reports.
Second confounders are the differences in nebuliser output. It is well known that the
different types nebulisers used show widely different mass outputs7 8 9. It is conceiv-
able that a high mass output of a large particle nebuliser counterbalanced the low
particle size efficacy. This effect of course lowers the discriminative power of the
study, favouring the conclusion of non-significant differences. So an accurate esti-
mation of the mass output is highly advisable, but most experiments did not control
this confounder.
To summarise, based the data in chapters 2 and 3, a relationship between the particle
size of bronchodilators aerosols and clinical effect seems highly probable, but not
confirmed due to experimental problems. Overlapping distributions of polydisperse
aerosols should be avoided by generating aerosols with a very narrow size distribu-
tion. Only then it is possible to discriminate between particle sizes. At the same time
the inhaled dose should be controlled tightly by correcting differences in mass out-
put. The study by Patel addressed the issue of overlapping size distributions: one
used a spinning top generator to generate monodisperse aerosols, but unfortunately in
that study a control of the dose was lacking4.
The aims of our studies are therefore:
1. to define the optimal particle size for bronchodilator drugs. The range of particle
sizes studied may not be too small: based on the modelling and in-vivo deposi-
tion studies, a range between 1 µm and 5 µm seems to be a reasonable choice.
Bronchodilators, as monodisperse aerosols, will be administered to asthmatic
patients under tight control of the dose. The selection of the best particle size is
then straightforward because the strongest dilation will be elicited by the optimal
aerosol size. These experiments will be carried out in both mild and severe
asthmatics, because the actual airway diameter can influence the choice of the
optimal particle size. (To ensure sufficient penetration in constricted airways a
smaller particle size might be warranted). Mutatis mutandis this also goes for
different types of bronchodilators: ß2-mimetics may require another aerosol for-
mulation than parasympathicolytics.
2. Having defined an optimal particle size, one than can determine how much mass
of such an optimal aerosol formulation one has to administer to obtain a bron-
chodilation equivalent to MDI’s. It is expected that the optimal aerosol dose is
lower. This then informs on the extent of the so called non-active (=non-dilatory)
part of MDI aerosols (the latter the result of generating non-penetrating parti-
cles).
3. Directly linked to that experiment one can ask oneself what then is the role, in
terms of adverse eff cts, of that non-dilatory part of the emitted dose is.
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1The optimal particle size for beta-drenergic aerosols in mild
asthmatics*
Introduction
The treatment of asthma and chronic obstructive pulmonary diseases (COPD) has
improved considerably with the introduction of drugs by inhalation. As compared to
oral administration, dosages could be decreased substantially and the incidence of side
effects was diminished considerably. Unfortunately, the currently available inhalation
preparations show one major disadvantage: only a small quantity of the administered
mass reaches the airways1. Part of the problems is caused by the fact that only highly
polydisperse aerosols are available. Such aerosols contain large particles, which are
not effective, because they deposit extrathoracical.
The site of deposition of the particles in the airways depends strongly on the way of
inhalation and the size of the particles. Targeting of deposition can be achieved by
adjusting the inhalation manoeuvre and the particle size. A way to improve the
efficacy therefore is to determine the optimal particle size, since adequately targeted
ß2-mimetic agents will induce the strongest decrease in airway obstruction2. The
deposition patterns of aerosols in the lung will be influenced, however, by the degree
of constriction of the airways, so one is forced to stratify patients. Only few studies
have focused on the relationship between particle size of a ß2-mimetic erosol and its
efficacy3 4 5 6 7. However, it is impossible to conclude from these studies, the optimal
particle size, since the results of the various studies are contradicto y.
To determine the optimal particle size we compared the effects of salbutamol aerosols
with variable diameters on the degree of lung function improvement in a group of
asthmatic patients with mildly impaired lung function. To do so we use monodisperse
aerosols because polydisperse aerosols contain overlapping particle size distributions,
which will obscure differences between larger and smaller particles.
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2Materials and methods
Patients
Eight mild asthmatic patients participated in the trial (3 women and 5 men). The
average age (sd) was 40 (10) years, the mean FEV1 (sd) was 72.3 (6.8) percent of the
predicted value. In all patients a bronchodilator response of >15% after inhalation of
200 µg salbutamol had been measured just before the trial. None of the patients were
smokers. All patients used corticosteroids by inhalation, cr moglycate or long-acting
ß2-mimetic agents were not used. Oral anti-asthma medication was not allowed.
Except the corticosteroids, their regular medication was discontinued 6-8 hours
before the start of the trial. All patients gave their written consent before the entry of
the trial, which was approved by the hospital ethics committee.
Aerosol generation
Monodisperse aerosols (geometric SD <1.2) were produced by a spinning top
generator8. A spinning top generator consists of a small disk, rotating at 12000 rpm.
Liquid is fed to the centre of the disk and the high centrifugal force causes droplets to
leave the rim of the disk. These droplets are all of the same size. These droplets are
dried by hot air and led to a small tank, from which the patients inhaled. The concen-
tration of the drug in the solution and the viscosity of it governs the diameter of the
resulting dry particles. Salbutamol solutions (50% water/50% ethanol) of 0.1%, 1%
and 10% were used to yield aerosols with a mass median aerodynamic diameter
(MMAD) of 1.5 µm, 2.8 µm, and 5 µm, respectively. Each time a patient was due to
start aerosol inhalation, the mass of salbutamol per litre of air and the particle
diameter of the dry aerosol particles in the tank were measured by an Aerodynamic
Particle Sizer 33 (TSI, St. Paul, Min). For each dose the volume of air inhaled was
calculated by dividing the dose by the mass of salbutamol per litre of air. If sufficient
aerosol-containing air had been inhaled, switching over to non-aerosol containing air
discontinued the aerosol inhalat on.
Procedure
Each patient was studied at the lung function laboratory with intervals of one week.
The baseline FEV1 during each session was not allowed to vary more than 10%. Each
3session consisted of 4 cycles, which consisted of measurement of the lung function 15
and 30 minutes after administration of the aerosol. A next cycle started within 5
minutes after the previous one. First, 5 µg salbutamol was administered, followed by
5 µg, 10 µg and 20 µg during the second, third and fourth cycle, respectively,
resulting in cumulative doses of 5 µg, 10 µg, 20 µg and 40 µg salbutamol. (All
dosages are expressed as µg delivered to the mouth). The inhalation manoeuvre
consisted of inhalation of the slow vital capacity with a flow of 40-60 L/min, followed
by a breath-holding period of 10 seconds and a slow exhalation. A hot wire ane-
mometer placed close to the mouth of the patient measured the inhalation flow and
volume. The amount of aerosol deposited in the anemometer was neglectable. Before
the aerosol inhalation the patients were taught to inhale and they had the opportunity
to correct the inhalation flow by watching an indicator connected to the anemometer.
Administration of the aerosols was done in a randomised single-blind manner. On the
first day a placebo aerosol was administered in order to facilitate early detection of
any adverse reactions of the patient to equipment or solvents. In addition, the placebo
measurement served to determine the spontaneous variability in airway obstruction
during the measuring period.
Lung function assessment
The lung function was assessed 15 and 30 minutes after inhalation of the aerosol. The
lung function assistant was not informed about the type of aerosol administered. The
Rtot was measured with a body plethysmograph, the FEV1, F C, and VC by means of
spirometry, and the PEF and MEF75/50/25 were derived from maximal expiratory flow-
volume curves.
Statistics
The change in lung function was expressed as a percentage of the predicted value.
Four dose-response curves were generated, one for each type of aerosol. These dose-
response curves were analysed for effects related to the type of aerosol (aerosol-size
effect), effects of increasing dosages (dose effect), and interaction between size and
dosage using repeated measurements anova9. Any differences between the measure-
ments at t = +15 and t = +30 minutes were evaluated with the paired T-test.
4The mean lung function improvement over all four dosages will be higher for the most
potent aerosol as compared to the less potent aerosols. In order to find out whether a
less potent aerosol deviates significantly from the most potent aerosol, it was
calculated how large the deviation between these means should be before it was fair
to speak of significance. In this respect the method of Schuirmann was applied, this
method is comparable to the LSD-test10. In all calculations an a-value of 0.05 was
considered to be significant.
Results
All 8 patients completed the four sessions. None of the values of the lung function
parameters, measured 30 minutes after administration of the aerosol differed signifi-
cantly from those measured 15 minutes after administration. Therefore, only an
evaluation is given of the measurements conducted 15 minutes after aerosol admini-
stration.
In Fig. 1 the dose-response curve for the FEV1 and peak flow are represented. In any
of the parameters no change was measured during the inhalation of placebo. The
evaluation of the dose effects demonstrated that for all lung function parameters
statistically significant differences existed between dosages, with the higher dosages
causing a stronger bronchodilation (p<0.05). The interaction between the dose and
the effects of the three types of salbutamol aerosols was non-significant for all lung
function parameters (p>0.1), which indicates that the dose-response curves run
parallel.
In evaluating the aerosol-size effect, the analysis of variance demonstrated significant
differences with reference to placebo for the FEV1 (p<0.01), the PEF (p<0.01), de
FVC (p<0.01), the MEF75 (p<0.01), the MEF50 (p<0.01) and the MEF25 (p<0.01).
This implies that all the dose-response curves of the salbutamol aerosols are located
higher than the placebo curves.  For the Rt t (p=0.116) and the VC (p=0.068) no
significant differences due to the different aerosol-sizes were demonstrable. The
reason for this is to be found in the strong spontaneous variability of the Rtot and/or
the minor improvement of the VC.
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Fig. 1 Dose-response curves for the FEV1 and peak flow
6Particle size of the aerosol (µm)Lung function
parameter 1.5 2.8 5
Significant
different
aerosols
FEV1 12.8(4.3) 14.6(6.5) 10.1(4) 2.8 vs. 5
FVC 8.9(5.6) 9.6(9.3) 7.9(6.6) NS
MEF25 12.1(6.6) 14.9(9.5) 9.2(7.9) 2.8 vs. 5
MEF50 15.2(6.7) 18.5(9.4) 12.1(6.2) 2.8 vs. 5
MEF75 17(4.4) 21.4(9) 14.6(5.6) 2.8 vs. 5
PEF 9(7.1) 15(7) 13.1(7.9) 2.8 vs. 1.5
Rtot -27.6(93) -84.3(92) -52.7(62.1) NS
VC 7(7.8) 8.1(9.4) 6(8.9) NS
Table 1 Mean (sd) improvement in lung function (%predicted) over all four
dosages per type of aerosol (NS= non significant)
A significant difference with reference to 2.8 µm aerosol will occur for the FEV1 if
the deviation between the means exceeds 2.9%, for the PEF this deviation should be
at least 5.9%, for the MEF75/50/25 at least 5.4%, 4.3% and 4.9%, respectively, and,
finally, for the FVC at least 9.4%. In the case of the FEV1 and the MEF75,50,25 a
statistically significant difference occurred between the 5 µm aerosol and the 2.8 µm
aerosol. For the PEF a significant difference was found between the 1.5 µm and the
2.8 µm aerosol. For the FVC the differences were too small to be significant.
Table 2 lists the mean improvements as %predicted with 95% confidence intervals
after administration of 40 µg salbutamol for all lung function parameters. Despite the
low dosage a significant improvement of the lung function can be observed. The
improvement in the VC was not significant.
None of the patients reported any adverse effects as a result of the experiment.
Lung function
parameter
Improvement (%
predicted) 95% confidence interval
FEV1 20.7 13.5 28.0
FVC 12.6 2.4 22.7
MEF25 26.9 20.6 36.9
MEF50 26.7 18.5 34.8
7Lung function
parameter
Improvement (%
predicted) 95% confidence interval
MEF75 28.8 06.4 37.6
Rtot -102.2 -29.0 -175.0
PEF 19.8 12.4 27.1
VC 9.3 -0.11 18.7
Table 2 Mean improvement in lung function (%predicted) following 40 µg
salbutamol administered as a 2.8 µm aerosol
Discussion
The increase in FEV1 and the MEF75/50/25 after the 5 µm aerosol differed significant
from the 2.8 µm aerosol, while there were no significant differences between the 1.5
µm and the 2.8 µm aerosol. The increase in the PEF was highest after the 2.8 µm
aerosol, not being significantly different from the 5 µm aerosol. No size-effect was
present in case of the VC, FVC and the Rtot. We were able to show these differences
in a relatively small group of volunteers. This is due to a low intrasubject variability
and the use of repeated measurement anova, which eliminates the interindividual
variability. Patel et al. also showed comparable differences in a small group of
volunteers3.
The lung has the capacity to intercept a large portion of the inhaled particles rapidly
and effectively by several mechanisms that cause particles to deposit on the mucous
membrane. Two important processes in this context are impaction and sedimenta-
tion11. Impaction means that particles are not able to follow changes in the direction
of the air stream and deposit. This mechanism is of particular relevance for large or
heavy particles. Sedimentation is a time-dependent process related to the velocity
with which particles fall down under the influence of gravitation. The speed of fall
becomes constant at the moment the resistance of the air is equal to gravitation.
These two mechanisms cause large particles to deposit in the upper airways, whereas
smaller particles escape from impaction and penetrate the airways more deeply. So a
deposition pattern in the airways is evident. Targeting the deposition towards a
segment of the airways can be achieved by selecting the right particle-size of the
aerosol or by adjustment of the breathing-t chnique2.
8It is possible that in the efficacy of ß2-mimetic agents a significant role is played by
the fact that the ß2-receptors are not uniformly distributed in the airways. In a number
of publications an increase in the number of receptors is reported in association with
distances further into the periphery of the lung12 13. Assuming that a greater effect is
obtained when the concentration at the receptor is higher, there is a ratio for matching
the deposition pattern of ß2-mimetics to the beta-adrenoceptor distribution.
In the present study we have based ourselves on the assumption that a more periph-
eral deposition was desirable. One way to achieve this is by a slow and deep inhala-
tion of the aerosols. In addition, the particles were reduced in size. Reduction in size,
however, cannot be continued without impunity. "Too small" particles are known to
have a terminal velocity that is so small that they hardly deposit. This implies that
there is an ideal particle size: not too large and not too small. The optimal particle
size will depend on a number of factors, i.e. the preferred deposition pattern, the
condition of the airways - in this context their diameter - and the inhalation technique.
We decided on an upper limit of 5 mm, because various studies have demonstrated
that particles with a MMAD above 5 µm only reach the airways to a limited extent14.
The lower limit of 1.5 µm was chosen on technical grounds (since both the spinning
top generator and the aerodynamic particle size  ar characterised by a functional
lower limit of 0.5 - 1 µm), and it has been documented that particleswith a MMAD
below 0.5 µm hardly deposit in the airways11.
In asthmatics Clay found that a 1.8 µm terbutaline aerosol induces a stronger
MEF50/25 improvement than a 4.6 µm or a 10.3 µm aerosol, whereas Patel found that
a 2.5 µm isoproterenol aerosol is more potent than a 5 µm aerosol3 7. Johnson
observed a significant difference between a 3.3 µm and a 7.7 µm salbutamol aerosol,
as did Ruffin between a 1.5 µm and a 3.2 µm isoproterenol aerosol; the outcome of
both studies was in favour of the smaller aerosol15 16. H wever, from all these data it
is not feasible to derive an optimal aerosol diameter. Moreover, the matter is
complicated by the negative findings of Hultquist and Mitchell: neither of these
investigators found any differences in potency between 1.5 µm and 4.8 µm aerosols
and 1.4 µm and 5.5 µm aerosols, e pectively4 5.
The results of our study demonstrate that in asthma patients with a mild airway
obstruction an aerosol with a MMAD of around 2.8 µm is to be preferred. The results
9of our study confirm the conclusion drawn by Patel that a 2.5 µm aerosol is more
potent than a 5 µm aerosol, but add to it that smaller aerosols are of no benefit. At
the same time an explanation is found for the negative findings of Hultquist and
Mitchell4 1. Both investigators have selected aerosol diameters that lead to minor
differences in potency. The discrepancy between these and other investigators thus is
merely an apparent one, to be attributed to the choice of particle sizes. The results
obtained by Clay are not easy to explain. However, this study the aerosols were
administered by means of various nebulisers7. It is possible that these nebulisers have
released divergent dosages, which might be interpreted as differences in potency.
The results of our study can be explained as follows: particles of 5 µm will be
deposited extrathoracical to a greater extent than the smaller particles, which are able
to penetrate the airways deeply. (In case of the 1.5 µm aerosol the smallest amount
can be expected extrathoracical). So small particles are to be preferred for a deep
penetration. However these particles deposit in minute quantities, so a deep penetra-
tion is at the expense of a lower mass deposited11. As for the PEF, it is striking that
the 5 mm particles perform better than the 1.5 µm particles: the bulk of the 1.5 µm
particles pass the central and the extrathoracic compartment. Here we see a contrast
with the more peripherally oriented lung function parameters: the 5 µm aerosol is
inferior to the two others. The 5 µm aerosol reaches the peripheral compartment to a
lower degree. The lower potency of the 1.5 µm aerosol can be ascribed to its limited
tendency to deposit. The fact that in all cases 2.8 µm particles induce a better effect
than 5 µm particles can be attributed to the difference in extrathoracic deposition17.
We did not measure the deposition patterns of these aerosols within the lung. So we
are not sure whether the differences in potency are to be ascribed to a better matching
between the ß2-receptor distribution and the deposition. One can state however that
the results of this investigation are in line with theoretical predictions of deposition
patterns17. The deposition of particles is never confined to a small segment of the
airways: one always encounters wide patterns. The calculations of Gerrity show that
in many segments of the airways comparable number of particles will deposit, while
the changes in the patterns due to differences in particle-size are not overwhelming18.
In asthmatics the same conclusions were drawn19. We therefore feel that the high
extrathoracical deposition of large particles and a low one for smaller particles
10
combined with an inherent low deposition for very small particles offers a good
explanation for our results. Without taking the receptor distribution into account.
In agreement with Patel and Mitchell we conclude that it is possible to induce
adequate bronchodilation with very small do ages3 4. In Table 2 we have included the
improvement of lung function after 40 µg salbutamol. This dosage is only one fifth of
frequently used MDI-dosages and one tenth of the dosages usually administered by
dry-powder inhalation (DPI). These low dosages lead to such a distinct bronchodila-
tion because they are monodisperse, contrary to the aerosols administered by metered
dose or dry-powder inhalers. In the usual polydisperse aerosols only a minor fraction
(depending on the formulation) of the mass will consist of particles <2.8 µm.
We conclude that in mild asthmatics the mean particle diameter of a ß2- im tic
aerosol should be around 2.8 µm for optimal improvement of the lung function. The
dosage of salbutamol can be reduced for such aerosols.
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1The optimal particle size for parasympathicolytic aerosols in mild
asthmatics*
Introduction
In a previous report we described the optimal particle-size of a ß2-mim tic erosol1. We
found that a salbutamol aerosol consisting of particles with a MMAD of 1.5/2.8 µm
elicited a higher degree of lung function improvement than a 5 µm aerosol. These results
were explained by adopting the hypothesis that the degree of penetration of particles into
the airways is an important factor. Particles need to pass the extrathoracic/upper airways
to reach the lower airways. In the extrathoracic/upper airways large particles are filtered
out of the inhaled air to a greater extent than smaller ones. Therefore the deposited
amount of particles in the lower airways is lower in case of large particles. In mild
asthmatics it appeared that this dose-reduction is large enough to cause a less intense
bronchodilatation.  It is not certain whether this outcome is transferable to other types
of bronchodilators, such as ipratropium bromide. The distribution of the receptors may
play a role. The ß2-adrenoreceptors are located mainly in the periphery of the airways,
the muscarinic receptors  are preferentially encountered in the central airways2 3. One c n
conceive that for a salbutamol particle it is harder to reach the receptor than for an
ipratropium bromide particle, therefore it must be smaller. On the other hand such small
particles will pass the upper airways better than large ones, missing the muscari ic
receptor. Our hypothesis is that the optimal particle-size of an ipratropium bromide-
aerosol will be larger than of a salbutamol-aerosol. Due to the resulting centrally orien-
tated deposition-pattern, the match to the receptor-distribution is better. To reject or
accept this hypothesis we determined the relationship between the particle size of an
ipratropium bromide-aerosol and the lung function improvement in asthmatic patients
with a mild reduction of the FEV1.
Materials and methods
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2Patients
Eight mild asthmatic patients participated in the trial (5 women and 3 men). The average
age (sd) was 39.6 (14.4) years, the mean FEV1 (sd) was 72 (14.3) percent of the pre-
dicted value. In all patients a bronchodilator response of ³15% after inhalation of 200
mg salbutamol had been measured just before the trial. None of the patients were smok-
ers. All, but one, used corticosteroids by inhalation, cr moglycate or long-acting ß2-
mimetic agents were not used. Oral anti-asthma medication was not allowed. Except the
corticosteroids, their regular medication was discontinued 6-8 hours before the start of
the trial. All patients gave their written consent before the entry of the trial, which was
approved by the hospital ethics committee.
Aerosol generation
Monodispersee aerosols (geometric SD < 1.2) were produced by a spinning top genera-
tor4. A spinning top generator consists of a small disk, rotating at 12000 rpm. Liquid is
fed to the centre of the disk and the high centrifugal force causes droplets to leave the
rim of the disk. These droplets are all of the same size. These droplets are dried by hot
air and led to a small tank, from which the patients inhale. The diameter of the resulting
dry particles is governed by the concentration of the drug in the solution and the viscosity
of it. Ipratropium bromide solutions (50% water/50% ethanol) of 0.1%, 1% and 10%
were used to yield aerosols with a mass median aerodynamic diameter (MMAD) of 1.5
mm, 2.8 mm, and 5 mm, respectively. Each time a patient was due to start the aerosol
inhalation, the mass of ipratropium bromide per litre of air and the particle diameter of
the dry aerosol particles in the tank were measured by an Aerodynamic Particle Sizer 33
(TSI, St. Paul, Min). For each dose the volume of air inhaled was calculated by dividing
the dose by the mass of ipratropium bromide per litre of air. If sufficient aerosol-
containing air had been inhaled, the aerosol inhalation was discontinued by switching
over to non-aerosol containing air.
Procedure
Each patient was studied at the lung function laboratory with intervals of one week. The
baseline FEV1 during each session was not allowed to vary more than 10%. Each session
3consisted of measurement of the lung function 30 minutes after administration of the
aerosol. From the previous study we learned that using monodi persee aerosols of these
size-range small dosages of drug (5-10% of a MDI-dosage) are needed, we therefore
decided to administer only 8 mg ipratropium bromide (dosage expressed as mg d livered
to the mouth). The inhalation manoeuvre consisted of inhalation of a slow vital capacity
with a flow of 40-60 L/min, followed by a breath-holding period of 10 seconds and a
slow exhalation. The inhalation flow and volume were measured by a hot wire ane-
mometer placed close to the mouth of the patient. The amount of aerosol deposited in
the anemometer was neglectable. Before the aerosol inhalation the patients were taught
to inhale and they had the opportunity to correct the inhalation flow by watching an
indicator connected to the anemometer. Administration of the aerosols was done in a
randomised single-blind manner. On the first day a placebo aerosol was administered in
order to facilitate early detection of any adverse reactions of the patient to equipment or
solvents. In addition, the placebo measurement served to determine the spontaneous
variability in airway obstruction during the measurement period.
Lung function assessment
The lung function was assessed 30 minutes after inhalation of the aerosol. The lung
function assistant was not informed about the type of aerosol administered. The Rtot was
measured with a body plethysmograph, the FEV1, FVC, and VC by means of spirometry,
and the PEF and MEF50/25 were derived from maximal expiratory flow-volume curves.
Statistics
The change in lung function was expressed as a percentage of the predicted value. These
changes were analysed for effects related to the type of aerosol (aerosol-size effect) using
repeated measurements anova5. In order to discover whether a less potent aerosol
deviates significantly from the most potent aerosol, it was calculated how large the
deviation between these means should be before it was fair to speak of significance. In
this respect the method of Schuirmann was applied, which method is comparable to the
LSD-test 6. In all calculations an a-value of 0.05 was considered to be significant.
4Results
All 8 patients completed the four sessions. In Table 1 the change in all lung function
parameters is represented. No significant change was measured in any of the parameters
during the inhalation of placebo.
In evaluating the aerosol-size effect, the analysis of variance demonstrated significant
differences with reference to placebo for the FEV1 (p<0.01), the PEF (p=0.001), the
FVC (p=0.034),  the MEF50 (p<0.001) and  the MEF25 (p=0.001). For the Rtot (p=0.202)
and the VC (p=0.052) no significant differences were demonstrable.
-20
-10
0
10
20
30
40
50
placebo 1,5 2,8 5
particle size (µm)
%
 p
re
d
 c
h
a
n
g
e
Fig. 1 Scatterplot of FEV1 improvement after administration of the different
aerosols, the mean improvement is depicted by the solid line
5-20
-10
0
10
20
30
40
50
60
placebo 1,5 2,8 5
particle size (µm)
%
 p
re
d
 c
h
a
n
g
e
Fig. 2 Scatterplot of MEF 25  improvement after administration of the different
aerosols, the mean improvement is depicted by the solid line
Particle size of the aerosolLung function
parameter 1.5 mm 2.8 mm 5 mm
Significant dif-
ferent aerosols
VC 13.6(13) 11.5(12.5) 7.7(7.8) NS
Rtot -74.4(73.2) -114.8(97.1) -104.5(135.9) NS
FVC 12.4(12.4) 13(12.5) 9.4(10.8) NS
FEV1 20.3(8.7) 23.7(12.1) 15.6(9.8) 1.5/2.8 vs. 5
MEF25 23.7(15) 19.3(14.7) 15.3(12.7) 1.5/2.8 vs. 5
MEF50 24.7(10.7) 24.7(12.1) 17.7(10.3) 1.5/2.8 vs. 5
PEF 21(7.2) 22(13.2) 16.6(12.4) NS
Table 1 Mean (sd) improvement in lung function (% predicted) after inhalation
of ipratropium bromide aerosols with different particle sizes (NS = non-significant)
A significant difference with reference to the best aerosol will occur for the FEV1 if the
deviation between the means exceeds 5.7%, for the PEF this deviation should be at least
7.5%, for the MEF50/25 at least 6.3% and 8.2%, respectively, and, finally, for the FVC at
6least 5.5%. In the case of the FEV1 and the MEF50,25 a statistically significant difference
occurred between the 5 mm aerosol and the 1.5/2.8 mm aerosol. For all other parameters
the differences were too small to be significant.
None of the patients reported any adverse effect as a result of the experiment.
Discussion
The increase in FEV1 and the MEF50/25 after the 5 mm aerosol was significantly less than
after the 1.5/2.8 mm aerosol. No differences due to changing aerosol sizes were detect-
able in case of the other lung function parameters. These findings strongly resemble our
earlier findings with salbutamol: in those experiments the optimal particle size was also
£2.8 mm1. In contrast to the previous study no aerosol-size effect was noticeable in case
of the PEF. Our initial hypothesis pointed in another direction. To achieve an optimal
match between the deposition-pattern and musc rinic receptor-distribution a central
deposition-pattern seemed logical. Centrally orientated patterns will occur after inhaling
large particles. Contrary to our thoughts the results of this study indicate that the optimal
particle size (=deposition patterns) for ß2-mimetics and parasympathicolytic drugs are
similar. Hence the distribution of the receptors, as reported in the literature, do not seem
to play an important role. The explanation we offer for these results is of a physical
nature. In our previous publication we suggested that the way particles penetrate into the
lower airways, combined with a local effect, explains all findings.  All, but especially
large, particles are filtered out quickly in the central airways due to a high impaction-
probability. Only small particles will escape from extrathoracical/central deposition7. The
dose in the lungs or lower airways therefore heavily depends on the filter characteristics
of the extrathoracic/upper airways. The "lung-dose" will be higher in case of small
particles. This is reflected by the increased bronchodilation after administration of the
1.5/2.8 µm aerosols.
In contrast to the earlier study we could not find a better PEF-improvement after the 5
µm compared to the 1.5 µm aerosol. If the theory is correct one expects that the smallest
particles pass the central airways and only a small amount deposit. As a result the
improvement of the PEF, which is highly influenced by the condition of the central
airways, should be lower. This not the case (although the statistical power to detect
7differences was comparable to the previous experiment). Sva tengren showed that in
some patients the cut-off point of the oropharynx, due to local anatomical structures, is
very low8. Two of the volunteers showed rather low lung function changes after inhaling
the 5 µm aerosol. Thereby reducing the mean improvement of all lung function parame-
ters and obscuring the differences between the effects of the 5 µm and 1.5 µm aerosols
of the PEF, as found before. These volunteers must "suffer" from a low oropharyngeal
cut-off point. This explanation underlines the importance of choosing an aerosol with a
small particle size and low geometric standard deviation (GSD).
Our results are in in accordance with those of Padfield, but not with those of Johnson9
10. Padfield showed that an aerosol with 35% of the particles £6.4 µm elicited a better
bronchodilatation than an aerosol with only 10% £6.4 mm. Johnson could not detect any
differences between aerosols with a median mass diameters (MMD) of 3.3 resp. 7.7 mm.
The author reported a lower whole lung (and local airway) dose after administration of
the largest aerosol with much of the coarse aerosol deposited extrathoracical. The
explanation for this negative finding was that the percen ual higher central deposition of
the 7.7 mm aerosol compensated for the lower total and local dose. In other words a low
central dose is to be preferred over a high peripheral one. We do not think that this is
plausible explanation. It suggests that the dose-response curve for centrally deposited
ipratropium bromide is steeper. However the reported dose-response curves of the
MEF25 are much steeper than of the FEV1. This fact is not consistent with the explana-
tion given.
Ipratropium bromide and salbutamol (or other ß2-mim tics) are frequently combined in
metered dose inhalers or nebulisers. It is believed that the combination induces larger
and/or longer b onchodilations than the single components. By definition both drugs will
be administrated in the same droplet or dry particle, thus showing the same particle-size
distribution. If ipratropium bromide would need a coarse aerosol to be most active and
salbutamol a fine one, the combination would be rendered less effective as the two drugs
delivered independently. Our finding that both drugs exhibit the same optimal particle-
size, makes such a combination a rational one.
We conclude that in mild asthmatics the mean particle diameter of a par sympathicolytic
aerosol should be 2.8 mm for optimal improvement of the lung function. As for ß2-
8mimetic aerosols the dosage, compared to conventional polydisperse aerosols can be
reduced for such aerosols.
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1The optimal particle size for ß2-agonist and anticholinergic aerosols
in patients with severe airflow obstruction*
Introduction
In two previous publications we reported on the optimal particle-size of ß2-agonist
and anticholinergic aerosols1 2. We demonstrated that in asthmatics, with a forced ex-
piratory volume in one second (FEV1) >70% of predicted, salbutamol and ipratro-
pium bromide aerosols consisting of particles with a median mass aerodynamic di-
ameter (MMAD) <2.8 µm elicited statistically significant higher degrees of lung func-
tion changes than a 5 µm aerosol. These findings were explained by taking into ac-
count the filter characteristics of the airways. Airways filter particles out of the in-
haled air: 5 µm particles deposit rapidly in the extrathoracic/upper airways, while
smaller particles escape rapid deposition and reach the dilatable parts of the airways
better than the 5 µm particles, resulting in higher local doses, assuming equal doses
administered3.
The narrower the airways are, the higher the tendency to deposit and particle deposi-
tion patterns shift to the central airways3. Heyder showed that 3.5 µm particles de-
posit preferentially in the alveoli of normal subjects, while in our previous study
smaller particles caused the greatest bronchodilatation4. To reach the smaller airways
in such cases, it maybe necessary that the particle size of the inhaled aerosol should be
decreased. In patients with severe airflow obstruction, aerosols with a smaller particle
size maybe more suitable.
We therefore carried out experiments to determine the most suitable particle size for
bronchodilator aerosols in patients with severe airflow obstruction.
Materials and methods
Patients
Eight patients started the trial (two women and six men). Due to personal reasons,
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2one patient dropped out, so seven completed. The average age (sd) of those seven
was 55 (4) years, the mean FEV1 (sd) was 37.9 (7.3) percent of the predicted value.
In all patients a more than 15% increase of baseline FEV1 after inhalation of 200 µg
salbutamol had been measured just before the trial. None of the patients were smok-
ers. All used corticosteroids by inhalation, d sodium cromoglycate and oral anti-
asthma medication were not used. Except for corticosteroids, their regular medication
was discontinued six to eight hours before the start of the trial, while long acting ß2-
agonists were stopped 15 hours prior to the start. All patients gave their written con-
sent before entry into the study, which was approved by the hospital ethics commit-
tee.
Aerosol generation
Monodisperse aerosols (geometric SD <1.2) were produced by a spinning top gen-
erator5 .A spinning top generator consists of a small disk, rotating at 12000 rpm. Liq-
uid is fed to the centre of the disk and the high centrifugal force causes identical sized
droplets to leave the rim of the disk. These droplets are dried by hot air and led to a
small tank, from which the patients inhale. The diameter of the resulting dry particles
is governed by the concentration of the drug in and the viscosity of the solution. Sal-
butamol and ipratropium bromide solutions (50% water/50% ethanol) of different
concentrations were used to yield aerosols with a MMAD of 1.5 µm, 2.8 µm, and 5
µm, respectively. Each time a patient was due to start the aerosol inhalation, the mass
of salbutamol or ipratropium bromide per litre of air and the particle diameter of the
dry aerosol particles in the tank were measured by an Aerodynamic Particle Sizer 33
(TSI, St. Paul, Min). This is a so called time of flight particle sizer and informs on
both the particle size distribution and the mass contained in the aerosol in µg per litre
of air. To calculate the volume of air to be inhaled, we divided the dose to be admin-
istered by the mass of salbutamol or ipratropium bromide per litre of air rendering the
litres to be inhaled. If sufficient aerosol-containing air had been inhaled, the aerosol
inhalation was discontinued by switching over to non-aerosol containing air.
Procedure
Each patient was studied at the lung function laboratory with intervals of one week.
3The baseline FEV1 during the sessions was not allowed to vary more than 10%. Each
session consisted of measurement of the baseline lung function and 30 minutes after
administration of the aerosol. Based on previous experience, we administered 20 µg
salbutamol and 8 µg ipratropium bromide (dosage expressed as µg delivered to the
mouth). The inhalation manoeuvre consisted of inhalation of a slow vital capacity
with a flow of 40-60 L/min, followed by a breath-holding period of ten seconds and a
slow exhalation. The aerosol was administered during the entire inhalation manoeu-
vre. The inhalation flow and volume were measured by a hot wire anemometer placed
close to the mouth of the patient. The amount of aerosol deposited in the anemometer
was negligible. Before the aerosol inhalation the patients were taught the inhalation
technique and they had the opportunity to correct the inhalation flow by watching an
indicator connected to the anemometer. Administration of the aerosols was done in a
randomised single-blind manner. On the first day a placebo aerosol was administered
in order to facilitate early detection of any adverse reactions of the patient to equip-
ment or solvents. In addition, the placebo measurement served to determine the
spontaneous variability in airway obstruction during the measurement period.
Lung function assessment
The lung function was assessed 30 minutes after inhalation of the aerosol. The lung
function assistant was not informed about the type of aerosol administered. The spe-
cific airway conductance (sGaw) was measured with a body plethysmograph, the
FEV1, forced vital capacity (FVC), and vital capacity (VC) by means of spirometry,
and the peak flow (PEF) and maximum expiratory flow at 75/50/25% of the forced
vital capacity (MEF75/50/25) were derived from maximal expiratory flow-volume
curves.
Statistics
The change in lung function was expressed as a percentage of the predicted value6.
Using repeated measurements analysis of variance (ANOVA) it was determined
whether significant differences were present due to a) the particle size of the aerosol,
b) the type of drug and c) the interaction between drug and aerosol-size7. A signif-
cant interaction, in this case, means that the difference between salbutamol and ipra-
4tropium bromide is not constant and depends on the particle size of the aerosol ad-
ministered. When a statistically significant change was observed, the within-group
mean sum of squares was used to calculate the least significant difference. In all cal-
culations an a-value of 0.05 was considered to be significant.
Results
All patients completed the study without noticeable side-effects. No significant
change was measured in any of the lung function parameters during the inhalation of
placebo. Nor could we show significant differences between the bronchodilator re-
sponse of salbutamol and ipratropium bromide. Comparing identical particle sizes
there were no significant differences between salbutamol and ipratropium bromide.
Particle size of the aerosolLung function pa-
rameter placebo 1.5 µm 2.8 µm 5 µm
sGaw -2.88* -14.46 -21.93 -12.86
FEV1 0.08* 3.57* 8.87 3.84*
MEF75 -0.43* 1.44* 4.85 1.95
MEF50 -0.30* 0.58* 4.23 1.17*
Table 1 Mean improvement in lung function (% predicted) after inhalation of
aerosols with different particle sizes or placebo. The improvements shown reflect the net
effects of the different particle sizes, not confounded by the type of bronchodilator used. An asterisk indi-
cates a significant difference versus the 2.8 µm aerosol.
Improvement (sd)
Lung function parameter
after 20 µg salbutamolafter 8 µg ipratropium bromide
sGaw -22.4% (17.3%) -21.4% (16.9%)
FEV1 8.5% (7%) 9.3% (4.1%)
MEF75 3.4% (4.6%) 6.3% (4.1%)
MEF50 3.4% (4.8%) 5% (3.2%)
Table 2 Mean improvement in lung function (sd, as % predicted) after inhala-
tion of a 2.8 µm salbutamol or ipratropium bromide aerosol.
With respect to the effects of different particle sizes of the aerosol administered, we
5found significant differences in case of the FEV1 (p<0.001), the MEF75 (p=0.02), the
MEF50 (p<0.001) and sGaw (p=0.01) (see Fig. 1). In Table 1 we depict for each lung
function parameter between which particle sizes these significant differences were
present. In Table 2 we list the improvements of various lung function parameters after
administration of 20 µg salbutamol and 8 µg ipratropium bromide respectively as 2.8
µm aerosols.
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Fig. 1 Improvement of the, SGaw, FEV1, MEF75/50 due to placebo or salbutamol
and ipratropium bromide aerosols of increasing particle sizes. The improvement is
presented as percentage change of the predicted value.
Discussion
In patients with a severe airflow obstruction the particle size of choice for an aerosol
is approximately 3 µm, both for ipratropium bromide and salbutamol. These results
are comparable to our earlier findings with salbutamol and ipratropium bromide in
mild asthmatics. In those experiments the greatest bronchodilation was elicited by
aerosols with a MMAD <2.8 µm1 2.
7We believe that these findings are explained by filtering by the extrathoracic/upper
airways. Large particles are filtered out quickly in the central airways due to a high
impaction-probability. Only small particles will escape from extrathoracic/upper air-
way deposition3. The dose of inhaled drugs in the lungs or lower airways therefore
heavily depends on the filter characteristics of the extrathoracic/upper airways. Due to
the fact that particles <2.8 µm pass the extrathoracic/upper airways better than the
larger 5 µm particles, the actual dose in the airways is higher.
The observation that 2.8 µm aerosol induced greater bronchodilation than the 5 µm
aerosol both in patients with mild and severe airway obstruction, suggests that the
degree of airflow obstruction in the lower airways is not the most important factor
determining response. We feel that the most likely explanation for the difference are
the filtering characteristics of the non co strictable extrathoracic/upper airways.
In contrast to the earlier studies we now found that the 1.5 µm aerosol induced sig-
nificantly less bronchodilation than the 2.8 µm aerosol. A likely explanation can be
found in differences of deposition patterns. Smaller particles will always pass the
central airways better than larger particles, so even in severely constricted patients a
more peripheral orientated deposition pattern of 1.5 µm particles can be expected.
Changes in lung function parameters are composed of changes in both central and pe-
ripheral airways. It is conceivable that in severely constricted patients the peripheral
airways are less able to dilate. Therefore, deposition of bronchodilators in these parts
of the airways results in less total dilatation. The smaller improvement of the periph-
eral lung function parameters strengthen this hypothesis. We have not visualised the
deposition patterns of our aerosols in the airways, therefore we can not prove this
explanation. The alternative explanation would be a low lung dose: small particles
deposit less well and are exhaled to a higher degree causing low pulmonary deposi-
tion. However, due to the severe constriction one expects a higher deposition prob-
ability, leading to less particles exhaled and higher doses8.
As in our previous experiments we used low dosages and obtained significant bron-
chodilation. We based the choice of administering only 20 µg salbutamol and 8 µm
ipratropium bromide on the assumption that the lung deposition of monodispers aero-
sols is very high compared to polydispers aerosols delivered by a metered dose in-
8haler. Many studies have shown that approximately 10-20% of the actuated dose
reaches the airways and is effective9. 10% of a standard 200 µg salbutamol dose is 20
µg as is 8 µg for a standard ipratropium bromide MDI-dose. We do not know the
relative efficacy of our formulations compared to MDI's, because this study was not
set up as a direct comparison. The prestudy-check of the patients, however, included
measurement of the reversibility after 200 µg salbutamol via MDI and it was found
that the mean (sd) FEV1-improvement was 7.6% (2.7%), compared to 8.5% (7%)
improvement after 20 µg salbutamol as a 2.8 µm aerosol. We feel therefore that it is
possible to induce clinically significant bronchodilation using low dosages of correctly
formulated bronchodilators.
We conclude that in patients with a severe airflow obstruction the most suitable parti-
cle size of a ß2-agonist and anticholinergic aerosol should be approximately 3 µm.
Significant bronchodilation is obtainable with 10% of standard MDI dosages.
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1The efficacy of a low dosed, monodisperse parasympathicolytic
aerosol compared to a standard aerosol from a metered dose
inhaler*
Introduction
In both mild and severe obstructed patients, monodisperse bronchodilator aerosols
(geometric standard deviation <1.2) with a median mass aerodynamic diameter
(MMAD) <2.8 µm induced a greater bronchodilation as compared to aerosols con-
sisting of particles with larger MMAD's1 2 3. In these experiments a bronchodilator
dose equal to 8 µg ipratropium bromide or 20 µg salbutamol was administered to pa-
tients, lead to clinically relevant bronchodilatations. These dosages constitute ap-
proximately 10-20% of the emitted dose of a standard metered dose inhaler (MDI)4.
However, due to a lack of a direct comparison with the bronchodilator effects of a
MDI, these experiments could not answer the question whether 8 µg ipratropium
bromide or 20 µg salbutamol will elicit therapeutically equivalent effects. To base
further research, these dosage choices needed validation. Therefore, we designed a
study to compare the bronchodilator effects of a low dosed, monodisperse 2.8 µm
bronchodilator aerosol with those of a conventional metered dose inhaler plus spacer,
which is generally considered to be the most optimal way to administer an aerosol.
Materials and methods
Patients
Ten outpatients (3 women and 7 men) with at least partially reversible airflow ob-
struction volunteered. The average age (sd) was 49.5 (14.3) years, the mean forced
expiratory volume in one second (FEV1) (sd) was 58.1 (17.3) percent of the predicted
value. Eligible patients showed a stable airflow obstruction and a more than 15% in-
crease of baseline FEV1 after inhalation of 200 µg salbutamol measured shortly before
the trial. None were allowed to be smokers. Corticosteroids by inhalation were al-
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2lowed and the dose kept stable, sodium cr moglycate and oral anti-asthma medica-
tion were not allowed. Some patient characteristics are given in table 1. Except for
corticosteroids, their regular medication was discontinued six to eight hours before
the start of the trial, while long acting ß2-m metics were stopped 15 hours prior to the
start. All patients gave their written consent before entry into the study, which was
approved by the hospital ethics committee.
Aerosol generation
Monodisperse aerosols (geometric sd <1.2) were produced by a spinning top gen-
erator5. A spinning top generator consists of a compressed air driven disk, rotating at
12000 rpm. Liquid is fed to the centre of the disk by a pump identical sized droplets
are expelled from the rim of the disk. By blowing hot air over the disk these droplets
are dried and subsequently transported to a small tank, from which the patients inhale.
The concentration of the drug in and the viscosity of the solution govern the diameter
of the resulting dry particles. An ipratropium bromide solution (1% in
50% water/50% ethanol) was used to obtain an aerosol with a MMAD of 2.8 µm.
Each time a patient was due to start the aerosol inhalation, the mass of ipratropium
bromide per litre of air and the particle diameter of the dry aerosol particles in the
tank were measured by an Aerodynamic Particle Sizer 33 (TSI, St. Paul, Min). This is
a so called time of flight particle sizer and gives information on both the particle size
distribution and the mass contained in the aerosol in µg per litre of air (an APS 33 can
not measure particles of a size exceeding 15 µm). To calculate the volume of air to be
inhaled, we divided the dose to be administered by the mass of ipratropium bromide
per litre of air rendering the litres to be inhaled. If 8 µg ipratropium bromide (dosage
expressed as µg delivered to the mouth) had been inhaled, the aerosol inhalation was
discontinued by switching over to non-aerosol containing air.
An ipratropium bromide containing metered dose inhaler (AtroventÒ, Boehringer
Ingelheim, batchno.: 95B28) was primed and connected to a spacer (AerochamberÒ,
Trudell Medical, London, Canada). One dose of 20 µg was fired into the spacer and
to ensure maximal evaporation of the aerosol, 5 seconds later the patient inhaled from
the spacer. Subsequently a second dose was administered in the same way within 10
3seconds after the first one. A dose of 40 µg is the standard dose approved by regula-
tors and does not reside on the top of the dose-response curve6. Between dosing the
inhaler was shaken and care was taken to reduce electrostatic charging of the spacer.
The particle size distribution and the mass of the aerosol as it leaves the spacer was
measured by the above mentioned APS 33 (n=5).
Procedure
Each patient was studied three times at the lung function laboratory with intervals of
one week. The baseline FEV1 during the sessions was not allowed to vary more than
10%. Each session consisted of measurement of the lung function at baseline and 30
minutes after administration of the aerosol. A double-dummy technique was used to
avoid bias due to differences in the inhalation equipment. In one session we adminis-
tered 8 µg ipratropium bromide from the spinning top generator and a placebo from
the MDI, in another session a monodisperse placebo aerosol and 40 µg ipratropium
bromide from the MDI, and in a third session just placebo's. Administration of the
aerosols was done in a radomised manner.
The inhalation manoeuvre from the spinning top generator consisted of inhalation of a
slow vital capacity with a flow of 40-60 L/min, followed by a breath-holding period
of ten seconds and a slow exhalation. The aerosol was administered during the entire
inhalation manoeuvre. The inhalation flow and volume were measured by a hot wire
anemometer placed close to the mouth of the patient. The amount of aerosol depos-
ited in the anemometer was negligible. Before the aerosol inhalation the patients were
taught the inhalation technique and they had the opportunity to correct the inhalation
flow by watching an indicator connected to the anemometer. The inhalation manoeu-
vre from the MDI plus spacer also consisted of an inhalation of a slow vital capacity
with a flow of 40-60 L/min, followed by a breath-holding period of ten seconds and a
slow exhalation. An erochamberÒ contains a flow indicator that gives of a warning
when the inhalation flow exceeds 40 L/min.
Lung function assessment
The lung function was assessed 30 minutes after inhalation of the aerosol. The lung
function assistant was not informed about the type of aerosol administered. The spe-
4cific airway conductance (sGaw) was measured with a body plethysmograph, the
FEV1, forced vital capacity (FVC), and vital capacity (VC) by means of spirometry,
and the peak flow (PEF) and the maximum expiratory flows at 75/50/25% of the
forced vital capacity (MEF75/50/25) were derived from maximal expiratory flow-volume
curves. Per determination three readings were taken and the best of three selected.
Statistics
The change in lung function was expressed as a percentage of the predicted value7.
Using a pre-post test repeated measurements analysis of variance (ANOVA) it was
determined whether significant differences, induced by the three types of aerosols,
were present between the bronchodilatations8. If a significant difference was present,
the mean square error of the ANOVA-procedure was used to calculate the least sig-
nificant difference. The statistical power was calculated. In all calculations an a-value
of 0.05 was considered to be significant.
Results
The MMAD (gsd) of the monodisperse aerosol was 2.8 (1.1) µm, that of the
‘MDI+spacer’ aerosol cloud 1.8 (2) µm. This means that respectively 84.4%, 50%
and 15.6% of the mass of the ‘MDI+spacer’ aerosol consists of particles £3.8 µm,
£1.8 µm and £0.9µm. The same data for the monodisperse aerosol are: £3 µm,£2.8
µm and £2.5 µm. The mass (sd) delivered to the mouth of the patient by the
MDI+spacer combination proved to be in total 11.6 ± 2.3 µg.
All patients completed the study without noticeable side-effects. Administration of
placebo did not induce significant bronchodilatations. With regard to the effects of
different aerosols administered, we found significant differences versus placebo in
case of the FVC, the FEV1, the sGaw, the PEF and the MEF75, but not for the
MEF50/25. No statistical differences between the monodisperse- and the MDI-aerosols
were found for any of the lung function parameters measured (Tabl  2). The statisti-
cal power to detect a difference was, in case of the FEV1, 99.8%, while any difference
between the mean FEV1-improvement exceeding 2.3% (equal to 107 ml) would lead
to a statistical significant difference.
5Patient no Age (years) Sex
Baseline FEV1
(% predicted)
FEV1-
reversibility vs.
baseline (%)
1 41 female 80 18.9
2 59 male 29.2 23.6
3 57 male 54.4 17
4 60 male 68.8 21.4
5 50 female 76.4 16.1
6 56 male 34.1 27.6
7 26 male 75.3 16,5
8 24 female 55.7 41
9 62 male 52,8 19.7
10 60 male 54,8 18.8
Table 1 Patient characteristics
Improvement (sd)
Lung
function
parameter
after pla-
cebo
after 40 µg
ipratropium
bromide from
a MDI+spacer
after 8 µg
monodisperse
ipratropium
bromide
p-value of the
difference versus
placebo
sGaw 10.4(19) 35.7(26.8) 29.3(19.6) 0.036
FVC 1.1(7.7) 10.7(7.9) 9.1(10.7) 0.004
FEV1 0.3(5.6) 7.2(5.5) 8.4(5.1) <0.001
peak flow -3.9(11.2) 7.1(6.9) 8.9(10.3) 0.003
MEF75 0(4.7) 9.8(7.8) 10.1(12.7) 0.005
MEF50 0.1(3.8) 6.7(10.9) 7.1(6.9) 0.061
MEF25 -0.8(3.9) 4.1(9.1) 9.8(7.8) 0.154
Table 2 Mean (sd) lung function improvement as % predicted after administra-
tion of placebo, 40 µg ipratropium from a MDI or 8 µg ipratropium as 2.8 µm
monodisperse aerosol.
6Discussion
We showed that bronchodilatations after administration of an 8 µg, 2.8 µm ipratro-
pium bromide aerosol did not differ from the higher emitted dose of a metered dose
inhaler. The number of patients studied was rather small. Therefore, the absence of
significant differences may be due to a low discriminative power. Enright reported an
intra-individual FEV1-variability of 119 ml in women and 162 ml in men and we used
these data for sample size calculations9. 8-10 patients appeared to be sufficient Being
able to detect differences smaller than the intra-individual variability, we feel we are
able to claim equivalence between the monodisperse and MDI-aerosol, because the
differences are smaller than the intra-individual variability and therefore clinical irrel-
vant.
Aerosols generated by metered dose inhalers all show a wide distribution of particle
sizes. A major part of the cloud consists of large particles which deposit in the extra-
thoracic/upper airways10 11. The drug-availability is therefore very low12. The high loss
of drug in the upper airways may cause (systemic) side-effects, because the drug still
can be absorbed from the upper airway mucosa (especially important in case of in-
haled steroids). In general terms: an aerosol from a MDI is composed of an effective
and a non-effective part, the latter consisting of large particles.
That non-effective part of a MDI-aerosol is unavoidably present. Aerosol generation
by MDI’s  is based on pressure and thus results in polydispers aerosols. The high
starting pressure delivers sufficient energy to break-up the fluid in small particles.
Towards the end of the generation cycle, the pressure in the metering valve will have
decreased, which is equivalent to large particles. Particle sizes can be reduced by i-
creasing the pressure in the metered dose inhaler or by decreasing the metered vol-
ume, but the effect of these measures is reported to be limited13. We have adminis-
tered an aerosol we consider to be optimal: it was monodisperse and contains those
particles previously shown to be most effective1 2 3. Compared to a MDI aerosol one
can say that we ‘removed’ the non-effective part and as a result the dose could be
lowered substantially. The only further improvement we see possible, is an even
stronger reduction of the dose. We think that the latter endangers an equivalent de-
gree of bronchodilatation. In previous experiments we have determined dose-
7response curves and noted that dosages lower than the one we administered now in-
duced less marked dilatations1. Noting the current equivalence between our low
monodisperse and the full MDI dose we feel that the 80% reduction of the latter is
the maximum one possibly can do without the danger of decreased efficacy. Re-
phrasing this argument we can say that only 20% of an emitted MDI dose elicits a
clinical effect. We have compared fixed dosages in stead of dose-response curves.
One might remark that another light can be shed on our conclusion of equivalence
when the 40 µg ipratropium bromide MDI dosage resides on the plateau of the dose-
response curve. In other words when 20 µg and 40 µg are therapeutically equivalent,
the finding of a 80% dose reduction is not universally applicable. In this respect we
like to point at the fact that 40 µg ipratropium bromide is currently the recommended
dose used by patients. That dose contains 80% of non-efficacious material due to its
formulation. The formulation of 20 µg is an exact copy of the 40 µg, is seems logical
to expect that of a 20 µg dose 80% is also non-efficacious.
Another possibility for improvement of aerosol characteristics is the use of spacers.
Large droplets impact on the walls of the spacer due to their high inertia and in this
way a spacer acts as a selecting device for aerosol particles. The result of both evapo-
ration and impaction is a smaller sized aerosol. The drawback is that a considerable
portion of the emitted MDI dose is lost within the spacer, which becomes relevant in
case of (very) high priced drugs. In case of the A r chamber® a loss of approximately
70% of the emitted dose was reported, which is in line with our findings14. The selec-
tion of smaller droplets by impaction and evaporation by an Aer chamber® leads to an
aerosol with a MMAD of 1.9 µm, which complies with the recent findings of Barry15.
An Aerochamber® delivers to the mouth of a patient an aerosol, which resembles in
mass output and MMAD, our monodisperse 2.8 µm aerosol. In that sense an A ro-
chamber® seems adequate. This finding underlines our conclusion that it is possible to
reduce the emitted MDI dose by improving aerosol characteristics: MDI + spacer
combinations are generally considered to be equivalent to a MDI, while the ‘emitted
dose’ of  MDI + spacer combination is lower.
Still a spacer is not a standard solution to the problem how to reduce the emitted
dose. Barry has also investigated the characteristics of other spacers and found less
8favourable selection characteristics. Some spacers had a much higher mass output
and/or coarser aerosols. A 80% reduction is not always possible with spacers and
therefore they do not constitute a standard solution. A hallmark for an efficient spacer
seems to be a 80% reduction of the emitted MDI dose and a MMAD of approxi-
mately 2-3 µm.
Our conclusion is that by administrating monodisperse aerosols of sufficiently small
size, the total inhaled bronchodilatator dose can be reduced without loss of efficacy.
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1Reducing adverse effects of inhaled fenoterol through optimisation of
the aerosol formulation
Introduction
In a previous experiment we showed that it is possible to reduce the dose of inhaled
bronchodilators by an optimisation of the aerosol formulation. The latter means gener-
ating only those particles, which proved to be most efficient i.e. 2.8 µm particles1. In
that experiment inhalation of 8 µg of a 2.8 µm monodisperse ipratropium bromide aero-
sol proved to be therapeutically equivalent to 40 µg from a conventional metered dose
inhaler plus spacer2. Aerosols generated by conventional metered dose inhalers all show
a wide distribution of particle sizes (polydisperse aerosols). Most mass delivered to the
patient consists of large particles, which mainly deposit in the extrathoracic or upper air-
ways and as we have shown, that mass does not contribute to the beneficial effect of the
drug2 3. On the other hand, some of the delivered mass consists of very fine particles, i.e.
<2.8 µm, which penetrate the airways up to alveolar levels, where absorption is, most
probably, quick and complete. The bronchodilator effects of these parts of the aerosol
cloud will be small, while our hypothesis is that they still may contribute to the occur-
rence of adverse effects. We conceived that the ineffective part of the aerosol cloud will
deposit on a mucosal surface where it is prone to absorption with systemic adverse ef-
fects as possible result.
In this report we describe the results of a placebo-controlled study to the adverse effects
of a 2.8 µm monodisperse fenoterol aerosol as compared to a conventional fenoterol
metered dose inhaler in a dose ratio 1: 5.
Materials and methods
Volunteers
Twelve healthy volunteers (8 women and 4 men) without pulmonary diseases partici-
pated in this study. The average age (sd) was 23.5 (2.6) years. None were allowed to be
smokers or to use any medication, expect from oral anticonceptives. All volunteers gave
their written consent before entry into the study, which was approved by the hospital
2ethics committee.
Dosages administrated
The dose-response curve of fenoterol adverse effects has been described repeatedly4, 5.
Therefore, to minimise volunteer load, we decided to use only fixed doses of fenoterol
i.e. 800 µg from the MDI and 160 µg in the form of the monodisperse aerosol. The 800
µg MDI dose was presumed to induce measurable though acceptable adverse effects.
Aerosol generation
Monodisperse aerosols (geometric sd <1.2) were produced by a spinning top generator6.
A spinning top generator consists of a compressed air driven disk, rotating at 12000
rpm. Liquid is fed to the centre of the disk by a pump identical sized droplets are ex-
pelled from the rim of the disk. By blowing hot air over the disk these droplets are dried
and subsequently transported to a small tank, from which the volunteers inhale. The
concentration of the drug in and the viscosity of the solution govern the diameter of the
resulting dry particles. An fenoterol solution (1% in 50% water/  ethanol) was used
to obtain an aerosol with a MMAD of 2.8 µm. Each time a volunteer was due to start
the aerosol inhalation, the mass of fenoterol per litre of air and the particle diameter of
the dry aerosol particles in the tank were measured by an Aerodynamic Particle Siz r 33
(TSI, St. Paul, Min). This is a so called time of flight particle sizer and gives information
on both the particle size distribution and the mass contained in the aerosol in µg per litre
of air. To calculate the volume of air to be inhaled, we divided the dose to be adminis-
tered by the mass of fenoterol per litre of air rendering the litres to be inhaled. If 160 µg
fenoterol (dosage expr ssed as µg delivered to the mouth) had been inhaled, the aerosol
inhalation was discontinued by switching over to non-aerosol containing air.
A fenoterol containing metered dose inhaler (Berot cÒ, Boehringer Ingelheim, the
Netherlands, batchno.: 96D23) was primed and connected to a non-static spacer device
(AerochamberÒ, Trudell Medical, London, Canada). One dose of 200 µg was fired into
the spacer and the volunteer inhaled from the spacer. Subsequently three additional
doses were administered in the same way within 20 seconds after the first one. Between
dosing the inhaler was shaken. Between sessions the spacer was immersed in a wa-
ter/detergent solution and just before the sessions air-dried to prevent build of electro-
3static charges.
Parameters measured
We selected the decrease in serum potassium level, the increase in finger-tremor,
changes in heart rate and blood-pressure as primary end-points. A secondary end-point
was the increase in specific airway conductance as a measure of the beneficial effect of
fenoterol.
The specific airway conductance (sGaw) was measured with a body pleth smograph
(Jaeger Masterlab, Wurzburg, Germany). Serum potassium was obtained through non
occluded venapuncture and subsequently determined by means of flame photometry and
reported in mmol/litre. Finger tremor was determined by using a displacement transducer
(Philips, the Netherlands, PR 9310)7. This transducer gives off a voltage related to the
actual tremor. Because tremor induces both positive and negative voltages, it was
squared and subsequently averaged over a period of one minute. Blood pressure was
obtained by the Riva-Rocci method and heart rate by manual counting over a period of
60 sec’s. The systolic and diastolic blood pressure were subtracted to obtain the so
called pulse pressure.
Procedure
Each volunteer was studied three times at the lung function laboratory with intervals of
one week. Each session consisted of measure nt of all parameters at baseline and 15
minutes after administration of the aerosol. A double-dummy technique was used to
avoid bias due to differences in the inhalation equipment. In one session we administered
160 µg fenoterol from the spinning top generator and a placebo from the MDI plus
spacer, in another session a monodisperse placebo aerosol and 800 µg fenoterol from
the MDI plus spacer, and in a third session just placebo's. Administration of the aerosols
was done in a randomised manner.
The inhalation manoeuvre from the spinning top generator consisted of inhalation of a
slow vital capacity with a flow of 40-60 L/min, followed by a breath-holding period of
ten seconds and a slow exhalation. The aerosol was administered during the entire inha-
lation manoeuvre. The inhalation flow and volume were measured by a hot wire ane-
mometer placed close to the mouth of the volunteer. The amount of aerosol deposited in
4the anemometer was negligible. Before the aerosol inhalation the volunteers were taught
the inhalation technique and they had the opportunity to correct the inhalation flow by
watching an indicator connected to the anemometer. The inhalation manoeuvre from the
MDI plus spacer also consisted of an inhalation of a slow vital capacity with a flow of 40
L/min, followed by a breath-holding period of ten seconds and a slow exhalation. An
AerochamberÒ contains a flow indicator that gives of a warning when the inhalation
flow exceeds 40 L/min.
Statistics
Using a pre-post test repeated measurements analysis of variance (ANOVA) it was de-
termined whether significant differences, induced by the three types of aerosols, were
present8. If a significant difference was present, the mean square error of the ANOVA-
procedure was used to calculate orthogonal contrasts between the formulations to de-
termine which formulations differed from each other. In all calculations an -value of
0.05 was considered to be significant. All data are presented as mean values with their
standard deviation.
Results
The results of the measurements of all parameters before and after administration of pla-
cebo, the monodisperse and the metered dose inhaler aerosol are depicted in Fig. 1. The
differences in serum potassium changes between the monodisperse and MDI-aerosol on
the one hand and placebo on the other were highly significant (p=0.004 resp. p<0. 1),
but also between the two active formulations (p=0.001). The monodisperse aerosol elic-
ited a mean (sd) fall of 0.27 (0.27) mmol/l, compared to 0.67 (0.18) mmol/l after the
MDI-aerosol. The tremor response showed an identical picture: between placebo and
actives a significant difference (p=0.001 resp. p=0.01) and between the actives
(p=0.029). The monodisperse aerosol elicited a mean (sd) increase of 0.07 (0.07) volt,
compared to 0.29 (0.34) volt after the MDI-aerosol. The changes in pulse pressure and
heart rate did not differ significantly from placebo or between the actives. The specific
airway conductance changes were significantly different between placebo and the actives
(p<0.001), but not between the two drug aerosols (p=0.87). An 0.31 (0.24) resp.
0.29(0.49) kPa-1sec-1 increase was noted after the monodisperse or MDI-aerosol.
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Fig. 1 Changes in serum potassium (m ol/l), tremor response (volt) and sGaw
(kPa-1s-1) due to placebo, 160 µg fenoterol as 2.8 µm monodisperse aerosol or 800
µg fenoterol from a MDI + spacer. * r sp. # indicates significant changes versus placebo or the
monodisperse aerosol.
Discussion
We have shown that administrating an optimised aerosol formulation, while preserving
the bronchodilating effects, can reduce systemic adverse effects of inhaled fenoterol. Our
group defined 2.8 µm particles as the best choice for bronchodilator aerosols: larger and
smaller particles showed a reduced fficacy1. Unfortunately these 2.8 µm particles con-
stitute only a small percentage of the emitted dose of a MDI: the bulk of the emitted
dose consists of less or even non-efficacious particle3. These less efficacious particles
are unavoidable due to the way MDI’s aerosols are generated, but increased dosages are
needed to compensate for the lower particle efficacy. By generating and administration
of the most efficacious particles we succeeded to lower dosages by 80% relative to the
emitted dose of a MDI2.
However, that less efficient part of the aerosol cloud is still prone to absorption after
deposition on mucosal surfaces in the upper airways and the potency to elicit systemic
adverse effects is of course not altered. The ratio of local efficacy over systemic potency
is therefore not identical for each particle size: larger and smaller particles will show a
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6more unfavourable ratio than the 2.8 µm particles. This means that the adverse effect
eliciting potency of such particles is stronger compared to the 2.8 µm particles.
The results of this study show that the larger part of the adverse effects of inhaled fe-
noterol are elicited by that less efficacious part of the aerosol cloud. At the same time it
is evident that a complete abolishment of adverse effects of inhaled drugs is not a realis-
tic goal. In our volunteers a decrease of the potassium serum level and an increase of the
finger tremor is still noticeable after the monodisperse aerosol. These changes were sta-
tistically significant, but clinically less important. The mean reduction of the serum po-
tassium level after the monodisperse aerosol was only 0.27 mmo /l at a dose equivalent
to 800 µg from a MDI. It is to be expected that higher dosages of any monodisperse
aerosol, as administered here, will elicit stronger adverse effects.
It will be evident that both large and small particles will show unfavourable local efficacy
over systemic potency ratios. The question now is which of these particles are most to
blame for eliciting adverse effects. This might be dependent on the drug administered.
Spacers are generally known to reduce the presence of large particles, which often com-
prise the majority of the mass delivered9. Using large volume spacers M eran and co-
workers showed that the osteocalcin levels fell less when a beclomethason MDI/spacer
combination was used, while Brown reported similar conclusions10 11. Thi  indicates that
large particles are to blame for systemic adverse effects. As said before these large parti-
cles constitute the bulk of the mass and an efficient absorption from the upper airways
and/or the gastro-intestinal tract results in a high systemic load. When gastro-int stinal
absorption is prevented or the drug inactivated through pre-systemic elimination, the ad-
verse effects eliciting capacity of large steroid particles is of course diminished and the
focus then changes to smaller particles.
Lipworth showed that lung bioavailability of salbutamol in severe asthmatics is reduced
compared to mild patients or healthy volunteers12. In s vere asthmatics peripheral depo-
sition will be reduced and the latter experiment indicates that absorption from the pe-
ripheral airways is more efficient compared to central compartment absorption. The
above suggests that small bronchodilator particles mainly contribute to systemic absorp-
tion and thereby to adverse effects. The use of an AerochamberÒ spacer device strength-
ens this assumption, because the adverse effects due to the MDI/spacer combination are
7significant. Dolovich showed both in healthy volunteers and in bronchitis patients that a
spacer considerably reduced the throat-deposition of a fenoterol MDI. In healthy volun-
teers the deposition in the lung periphery slightly increased, but in patients i did not
change13. This means that the effect of an Aerochamber® is an efficient removal of the
larger particles, which now can not enter the airways or the gastr -intestinal tract.
Therefore the small particle fraction is the most likely candidate for eliciting adverse ef-
fects.
In this respect is seems miraculous that a small 2.8 µm aerosol still elicits significantly
less adverse effects as the small particle fraction of a MDI. The latter, however, is a
polydisperse aerosol even now containing smaller and larger particles. Especially the
smaller particles are efficiently absorbed because they deposit in the airway regions with
the thinnest mucosa. Recent data on HFA-BDP MDI’s show that small changes in
MMAD from 2.5 to 1.1 µm increased the lung bioavailability by a factor 2 14. Appar-
ently 2.8 µm particles show a deposition pattern which is a better compromise between
penetration, effect and absorption as other particles.
Spacers are known to alter the particle size distribution of MDI aerosol clouds. How-
ever, the data reported by Dolovich do show that the use of an Aerochamber® does not
invalidate the results of this experiment: the mass depoisted in the lung and the deposi-
tion pattern are similar relative to the MDI alone, so our results will be valid for fe-
noterol MDI’s too13. Furthermore we ensured that build up of electrostatic charges dur-
ing the use of the Aerochamber® was minimal. Even, if some of the respirable fraction
would be lost due to electrostatic phenomena, the results stay valid. The adverse effects
noted are then due to a somewhat ‘emitted’ dose from the MDI/spacer, only showing
the potency of the drug to elicit adverse effects.
Previously we showed therapeutic equivalence of an 8 µg, 2.8 µm ipratropium bromide
aerosol to a 40 µg MDI aerosol. This equals a five times higher potency of the monodis-
perse aerosol (based on the nominal dose) and we adopted the same dosage ratio for this
experiment, although we now used fenoterol. We believe this is a valid approach, be-
cause 1] the optimal particle size for a salbutamol and ipratopium bromide aerosol
proved to be the same, 2] the particle size distributions of a fenoterol and ipratropium
bromide MDI aerosols will not differ much and 3] aerosol deposition patterns are gov-
8erned by the aerodynamic characteristics of particles, which are not significantly influ-
enced by the chemical nature of the drug its lf1 15. Therefore our choice of a 1:5 ratio in
dosages is a valid one.
Cardiovascular parameters, like blood pressure and heart rate, did not change much. We
feel that these parameters react in a more blunt way than tremor or serum potassium.
Earlier studies by Newhouse showed that cardiovascular parameters changed signifi-
cantly versus baseline at dosages exceeding 1200 µg fenoterol5. In two studies in asth-
matic patients the cardiovascular dose-response curves were flat up to 1000 µg res .
800 µg dosages and only become steeper at higher dosages16, 17. Having administered
800 µg, it is no surprise to us that we did not encounter significant changes in these pa-
rameters.
We have carried out these experiments in healthy volunteers, who did not use ß2-mimet-
ics and, by definition, were not tolerant to the action of fenoterol. As known, long term
users of ß2-mimetics might show tolerance, resulting in diminished beneficial or adverse
effects. The relevance of this study is, therefore, changed when long term users due to
tolerance do not suffer from adverse effects. In the literature tolerance has been debated
repeatedly, but a consensus on its impact has not been reached18, 19. Fenoterol has been
reported not to induce tolerance20. Wh n tolerance is an issue, compared to long term
users, healthy volunteers will be better discriminators and they will resemble to short us-
ers of ß2-mimetics. Besides that, we believe that our results can be extrapolated to long
term bronchodilators users. Development of tolerance to fenoterol is a pharmaco-
dynamic phenomenon and not influenced by the formulation of the aeros l. So it is un-
likely that the difference, noted now between the adverse affects of the two active prepa-
rations, will change on the long run.
In conclusion we can say that a change in aerosol formulations towards monodisperse
aerosols will reduce systemic adverse effects of ß2-mimetics, but it is unlikely that they
will disappear entirely, especially at higher dosages.
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1Summary, discussion and future research
Summary
The aim of our research was to determine the optimal aerosol formulation for inhaled
bronchodilators and subsequently to what extent dose and adverse effects could be
lowered.
In chapter 2 of this thesis the most relevant deposition mechanisms (impaction,
sedimentation and Brownian movement) are presented and elaborated. These mecha-
nisms, which all show their own characteristics, are related to the size of the inhaled
particle. Impaction is caused by the inertia of large particles, which cause them to
leave the airstream and to collide with the mucosa. The particles are too heavy or
travel too fast to follow bends in the bronchial tree. Sedim ntation is a time-
dependent process: due to gravity particles fall and the velocity reached is related to
their size. The smaller the particle, the lower their terminal velocity will be and
therefore small particles need more time to reach the mucosa. They have the capacity
to penetrate the smaller airways together with low deposition rates. When they are
‘too small’, the sedimentation time frequently exceeds that of a complete breathing-
cycle and these particles will be exhaled almost completely. Brownian movement is
only of importance for very small particles and of less interest for th rapeutic aero-
sols, due to their low total mass. Deposition is a physical process and each mecha-
nism is can be expressed in mathematical equations enabling researchers to build
models. The most elaborated model, that of Findeisen and followers, is reviewed.
Consensus exists on the general pattern of deposition: large particles impact in the
upper or extrathoracic airways, while smaller particles penetrate the airways further.
The number of depositing particles is related to their size: the smaller the size, the
lower the number. A deposition minimum is present with particles of 0.5 µm. Data
on the so-called regional deposition indicate that deposition patterns within the air-
ways are not circumscript, but widespread. The amount of spread is related to the
width of the size distribution of an aerosol, the stronger that width, the stronger the
spread. Obstruction of airways leads to an increased central depositio .
Chapter 3 deals with aerosol deposition in healthy subjects. The deposition pattern,
derived from modelling, is confirmed by these in-vivo experiments. The extratho-
2racic deposition increases rapidly as particle size increases. The major part of parti-
cles over 6 µm deposit in extrathoracic airways, while smaller particles may end in
the alveoli. The bronchial deposition is relatively low with a maximum of 20%. Next
to size, the inhalationflow and volume heavily influence deposition. An increase in
volume increases deposition, while the reverse is true for the flow. From particle
size, inhalationflow and volume a researcher can predict the total deposition. Con-
ceivably, lack of control of these parameters in an experiment increases the variance
of the deposition pattern.
In asthmatic subjects particle deposition is increased and related to the extent of the
bronchobstruction. In these patients the deposition patterns, as measured by g-
cameras are patchy and not uniformly distributed.
Deposition of therapeutic aerosols is reviewed in chapter 4. The deposition charac-
teristics are strongly dependent on the inhaler or nebuliser used. Metered dose inhal-
ers are capable to deliver 10-20% of the emitted dose to the lower airways. The aero-
sols they generate, are polydisperse and the bulk of the emitted mass consists of large
particles, which deposit in the upper airways. Spacers decrease upper airway deposi-
tion, although this effect varies between the different devices. Dry powder inhalers
lack some of the drawbacks of metered dose inhalers, but the efficacy may nega-
tively be influenced by the inspiratory effort of the patient.
Only in few experiments the relationship between particle size and therapeutic effect
has been investigated and unfortunately the outcome is contradictory. Some re-
searchers do not show differences in efficacy for particle sizes below 5 µm, the only
important factor is to be smaller than 5 µm. However, others do show differences in
that region: a 2.5 µm aerosol appeared to be more potent than 5 µm aerosols. Many
factors can be responsible for these different results. For instance the use of different
nebulisers can lead to differences in administered dosages and (highly) polydisperse
aerosols. Depending on the severity of these confounding factors a size-efficacy re-
lationship can be missed.
In chapters 6 to 10 the results of our experiments are presented, which (in summary)
showed that:
1. in mild and severe obstructed patients the strongest bronchodilation is
elicited by 2.8 µm monodisperse albutamol or ipratropium aerosols,
32. 8 µg ipratropium bromide as 2.8 µm monodisperse aerosol elicits an equi-
valent bronchodilation as 40 µg from a standard metered dose inhaler,
3. adverse effects of such a low dosed monodisperse aerosol are
significantly less compared to a standard metered dose inhaler.
In the first experiment 8 stable asthmatics with a FEV1 of 72% of the predicted value
inhaled 3 types of monodisperse salbutamol aerosols, with particle sizes of 1.5 mm,
2.8 mm and 5 mm, respectively, and a placebo aerosol (chapter 6). The volunteers
inhaled cumulative dosages of 5 µg, 10 mg, 20 mg and 40 mg salbutamol, followed by
lung function measurements. The dose-response curves were analysed with repeated
measurements anova. For the FEV1 and the MEF75/50/25 the 2.8 mm aerosol induced a
significant better bronchodilation than the 5 mm aerosol. In case of the PEF the 1.5
mm aerosol elicited a significantly smaller improvement than the 2.8 mm aerosol. No
particle size effects were noticeable in case of the VC, FVC and the Rtot. From these
results it was concluded that in mild asthmatics the particle size of choice for a ß2-
mimetic aerosol should be around 2.8 mm.
In the second experiment mild asthmatics (FEV1>70% of predicted) inhaled mono-
disperse ipratropium bromide aerosols, with the same particle sizes as above (chapter
7). The volunteers inhaled only 8 mg ipratropium bromide, followed by lung function
measurements and evaluated. Again, according to the changes in FEV1 d MEF50/25
the 1.5/2.8 mm aerosol induced a significant larger bronchodilation than the 5 mm
aerosol. No particle size effects were noticeable with regard to changes in Rt t, VC,
FVC and PEF. In mild asthmatics the particle size of choice for a parasymp thico-
lytic aerosol should also be £2.8 mm.
Logically the next experiment was carried out in patients with more severe airflow
limitations (chapter 8). Seven stable patients with a mean FEV1 of 37.9% of the pr-
dicted value inhaled monodisperse salbutamol and ipratropium bromide aerosols,
with particle sizes of 1.5 µm, 2.8 µm and 5 µm, respectively, and a placebo aerosol.
The volunteers inhaled 20 µg salbutamol and 8 µg ipratropium bromide, followed by
lung function determination and evaluation was performed as mentioned above. The
2.8 µm aerosol induced greater improvements in FEV1, sGaw and MEF75/50 than the
other particle sizes. In patients with severe airflow obstruction the particle size of
choice for a ß2-agonist or anticholinergic aerosol should also be approximately 3 µm.
4To discover whether the bronchodilator effects of these low dosed monodisperse
aerosols differed from those of standard dosages elivered by metered dose inhalers,
we carried out a comparative trial (chapter 9). 10 stable outpatients, with a mean
FEV1 of 58.1 % of the predicted value, inhaled a placebo aerosol, 8 µg of a 2.8 µm
monodisperse ipratropium bromide aerosol and 40 µg from a metered dose inhaler
plus spacer, followed by lung function measurements and analysis by repeated meas-
urements analysis of variance. Greater improvements compared to placebo were evi-
dent for the FVC, the FEV1, the sGaw, PEF and the MEF75. In these cases the low
dosed 2.8 µm aerosol proved to be equivalent to the higher dosed metered dose in-
haler. So, by changing the polydisperse characteristic of inhaled aerosols to a mono-
disperse pattern, the dose of the drug administered can be reduced by 80% without a
loss of efficacy.
Subsequently we compared the adverse effects of 160 µg fenoterol in the form of a
2.8 µm monodisperse aerosol to those of 800 µg inhaled as a conventional metered
dose inhaler aerosol + spacer (chapter 10). Healthy volunteers (8 women and 4 men)
participated in this study and inhaled in random order placebo, the monodisperse and
the MDI aerosol. Changes in serum potassium, finger tremor, blood pressure, heart
rate and specific airw y conductance were measured before and 15 min after admini-
stration. Compared to placebo the active aerosols elicited a significant similar im-
provement of airway conductance and adverse effects. Potassium levels decreased by
0.27 mmol/l after the monodisperse aerosol, while the MDI lowered them by 0.67
mmol/l (p=0.001). Finger tremor also increased less. Changes in the cardiovascular
parameters were not significantly different from placebo. From these results it can be
concluded that changing the formulation of MDI aerosols enables reduction of ad-
verse effects.
Discussion
The first main conclusion from these experiments is that in patients with mild and
severe airflow limitation, both for ß2-mimetics and parasympathicolytic drugs the
optimal particle size is ±3 µm. It also appears is that administration of these optimal
sized aerosols can lead to a significant reduction of adverse effects.
The first conclusion can be explained by the existence of an upper airway filter. The
extrathoracic and upper airways function as an effective filter for large particles,
5protecting the lower airway against a high load of dust or other possibly harmful
materials. Administration of large particles is therefore inefficient, because these are
lost in the upper airways filter leading to low dosages in the lower airways. This may
result in a low therapeutic effect. This phenomenon occurs both for ß2-mimetics and
parasympathicolytic aerosols and offers an explanation for the lower efficacy of the 5
µm aerosols, which we found in all experiments. In this respect the calculations of
the regional deposition by Gerrity et al. are highly informative1. For 5 µm particles
they show a predominant upper airway deposition, while the lower airway deposition
is lower compared to the 2 and 3 µm particles. The experimental data by Svartengren
et al. on the cut-off characteristics of the oropharynx underline the importance of the
upper airway filter2.  Moreover, it has to be taken into account that ß2-mimetics and
parasympathicolytic aerosol particles will be hygroscopic to a certain extent. In a
moisture environment, their size will grow and thereby the upper airway deposition
of the larger particles. 5 µm particles grow into much larger particles than 2.8 µm,
favouring their upper airway deposition.
Having explained the reasons for the low 5 µm efficacy, the differences between the
2.8 µm and the 1.5 µm aerosols need explanation. We expected that for ß2-mimetics
and parasympathicolytic aerosols, due to the differences in receptor distributions,
different optimal particle sizes would appear. A more centrally orientated deposition
pattern for parasympathicolytic drugs seemed logical and our results confirm this
hypothesis (2.8 µm more potent than 1.5 µm). Maybe the deposition pattern of 5 µm
particles would be better, in the sense of an even better fit to the receptor distribution.
However, if this would be the case, the low penetration and dose apparently out-
weighs the closer fit to the receptor distribution. In other words, an optimal fit be-
tween deposition pattern is of relatively low value when the deposited mass is (very)
low. An ill-fitting pattern with higher local masses is then preferable.
For ß2-mimetics it might have been expected or argued that 1.5 µm aerosols are a
better choice, because of a better fit to the receptor distribution. We feel that a com-
bination of effects can explain the ß2-mimetics results. First, more smaller particles
are exhaled than larger particles, even in asthmatics. The experiments by Schiller-
Scotland et al. clearly show an almost twice as high deposition for 3 µm particles
compared to 1 µm particles. The differences in deposition rates are less pronounced
in asthmatics compared to healthy volunteers, but they are present3. So it is xpected
6that 2.8 µm aerosols are equivalent to higher dosages and hence more potent. Appar-
ently, the dose outweighs the deposition pattern.
It has to be realised that depositions patterns are never circumscript. The data by Ger-
rity et al. indicate that the deposition patterns of 1 µm, 2 µm and 3 µm particles in
the lower airways do not differ strongly. The spread of particles is more or less com-
parable, but the mass deposited is higher for the 3 µm particles. Therefore when the
deposited dose is higher with comparable deposition patterns, the dose definitely
outweighs the deposition patterns.
The results in patients with severe airflow limitations can be explained by the same
principles. 5 µm particles hardly will enter the lower airways. The function of the
upper airway filter will not be highly different from that of mild asthmatics or
healthy subjects. One might have expected that the penetration of 1.5 µm particles
into constricted airways would be the most optimal, but this proved not to be true.
The deposition of 1.5 µm particles will always be lower than that of 2.8 µm particles
and apparently the latter reach the ß2-receptor in sufficient numbers. Again dose
outweighs the deposition pattern.
In the explanations above the nature of the drug inhaled hardly plays a role. Inhaled
particle deposition is a physical process, not linked to the chemical nature of the
drug. The aerodynamic particle size is not directly influenced by the chemical struc-
ture, except for the density and h groscopy. Density only plays a minor role, because
a density increase by a factor of eight increases the aerodynamic size only by a factor
two. So the above relationship between size and efficacy is most probably true for all
inhaled drugs, the most conceivable exceptions being receptor distributions peaking
in the upper airways or in the alveoli.
Metered dose and dry powder inhalers both generate polydisperse aerosol clouds.
Therefore it is predicted that the lower airway deposition (as percentage of the emit-
ted dose) is low and that the dose can be reduced substantially if the deposition pat-
terns can be improved. Most of the larger particles deposit in the upper airway filter
and unfortunately is absorbed from the local mucosa or from the gast -intestinal
tract after being swallowed, which may result in systemic adverse effects. Elimina-
7tion of the large particles reduces the systemic load and adverse effects and offers a
reasonable explanation for our findings.
However, any drug deposited in the lower airways is also prone to absorption o the
systemic circulation, which may lead to adverse effects. The severity and frequency
of adverse effects will be lower with optimal formulated aerosols. Nevertheless,
rapid deactivation of absorbed drug is necessary to eliminate this contribution to
systemic adverse effects. Such deactivation must occur before the drug occupies r-
ceptors in the body, which may result in requirements of a deactivation within sec-
onds, regarding the circulation time of the blood.
Future research
If it were true that the character of the drug plays an unimportant role for c icoste-
oids a similar optimal particles size would be valid as for bronchodilators and a sig-
nificant reduction of steroid adverse effects would be possible. There is however, one
parameter, which is different for steroids. Bronchodilators are all water-soluble and
therefore hygroscopic. Steroids are hydrofobic and therefore growth to moisture ab-
sorption can be minimal or absent. This may lead to a less prominent particle size vs.
efficacy relationship. This will need further investigations.
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Fig. 1 Distribution of droplets produced by a piezo-electric inkjet printhead.
The Y-axis depicts the cumulative mass, 50 % of the aerosol mass being smaller than 24.5 µm and
100 % smaller than 36 µm.
8Generating narrow distributed (=monodisperse) aerosols may be an important step
forward in improving therapeutic quality. Currently several options being investi-
gated to produce a portable monodisperse aerosol generator. Preliminary experiments
with the head of inkjet printers show that these devices produce monodisperse aero-
sols, although the droplets are still too large for inhalation. These heads need there-
fore to be rdesigned to produce smaller droplets.
Aerosols based on the Taylor cone principle are another option4. When a low con-
ductive fluid is pumped through a steel needle, which is connected to a 10 kV source,
fluid will not drip from the tip of the needle, but form a cone. The high electrical
charges now forces many identical shaped droplets to leave the tip of the cone. The
size of these droplets is governed by only a few parameters, which can be easily
controlled. The high 10 kV voltage can be supplied by batteries because currents are
very, very low.
In the near future we expect that technical problems will be solved and that inhalers
with a better defined aerosol output come available to the patient. Therefore it is ex-
pected that through these measures the quality  of anti s hma therapy will improve.
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1Samenvatting, bespreking en toekomstig onderzoek
Samenvatting
Het doel van ons onderzoek was de optimale formulering van luchtwegverwijdende
aerosolen en in hoeverre doseringen en nevenwerkingen gereduceerd konden word n.
In die vraagstelling speelt de depositie en de grootte van de geïnhaleerde deeltjes een
cruciale rol.
In hoofdstuk 2 van dit proefschrift worden de meest relevante depositiemechanismen,
zijnde impactie, sedimentatie en Brow se beweging geïntroduceerd en nader uitge-
werkt. Deze mechanismen, welke alle een eigen karakter bezitten, zijn gerelateerd aan
de grootte van het geïnhaleerde deeltje. Zo is impactie gebaseerd op de inert e van
grote deeltjes. Deze deeltjes zijn simpelweg te zwaar of bezitten een te hoge snelheid
om de bochten van de bronchiaalboom te kunnen volgen. Zij verlaten de luchtstroom
en botsen tegen het slijmvlies. Sedimentatie is daarentegen een tijdsafhankelijk proces.
T.g.v. de zwaartekracht vallen deeltjes naar beneden en de snelheid, die zij daarbij be-
reiken, is afhankelijk van de afmetingen: des te kleiner het deeltje is, des te lager die
terminale valsnelheid. Zij dringen diep door in de luchtwegen met e n geringe neiging
om neer te slaan. Wanneer zij ‘te klein’ zijn, is de tijd nodig voor sedimentatie zo
groot dat die uitgaat boven de duur van een in- en uitademingscylus. Zij worden
daarom vrijwel geheel weer uitgeademd. Brownse beweging is alleen van belang bij
zeer kleine deeltjes en daarmee niet interessant voor therapeutische aerosol n, omdat
de totale massa van deze deeltj s rg laag is.
Depositie is een fysisch proces en elk mechanisme kan worden beschreven middels
mathematische vergelijkingen, hetgeen het onderzoekers mogelijk maakt om modellen
te bouwen. Het meest uitgewerkte model, dat van Findeisen en navolgers, wordt in
dit proefschrift verkend. Er bestaat overeenstemming over het algemene karakter van
de berekende neerslag. Grote deeltjes impacteren in de extrathoracale of bovenste
luchtwegen, terwijl klein re deeltjes verder in de luchtwegen doordringen. Het aantal
neergeslagen deeltjes is wederom gerelateerd aan de grootte: des te kleiner het deel-
tje, des te lager de neerslagkans. Een minimum wordt geobserveerd bij deeltjes van
0.5 µm. Gegevens m.b.t. de regionale depositie laten zien dat depositiepatronen in de
2luchtwegen nooit tot een smal gebied gelokaliseerd, maar altijd sterk gespreid zijn.
Hierbij geldt dat een brede aërosolgrootte verdeling, gelijk staat met een sterkere v r-
spreiding van de depositie over de luchtwegen. Vernauwing van de luchtwege leidt
altijd tot een toename van de depositie.
Hoofdstuk 3 van dit proefschrift behandelt de luchtwegdepositie van de aerosolen in
gezonden. Het karakter, bekend uit de modelstudies, wordt door in-vivo expe imen-
ten bevestigd. De extrathoracale depositie neemt snel toe wanneer de deeltjesgrootte
oploopt. Het grootste gedeelde van 6 µm deeltjes deponeert extrathoracaal, terwijl de
kleinere deeltjes vooral in de alveoli neerslaan. De depositie in de br nchi is r latief
laag met een maximum van ongeveer 20%. Naast de deeltjesgrootte zijn het
inhalatievolume en de inhalatieflow van groot belang. Een toename van het volume
doet de depositie stijgen, terwijl het omgekeerde het geval is voor de inhalatieflow.
Wanneer men deeltjesgrootte, inhalatieflow en -volume kent, is het mogelijk om de
totale depositie te voorspellen. Gelet op het belang van deze factoren, is het
noodzakelijk deze parameters in elk experiment nauwkeurig te standaardiseren, om de
depositie-variabiliteit te beperken. In astmatici blijkt de deeltjesneerslag te zijn
toegenomen, afhankelijk van de mate van bronchusobstructie. De depositiepatronen,
zoals gemeten met gammacamera's zijn vlekkerig en verre van uniform.
De depositie van therapeutische aerosolen wordt beschouwd in hoofdstuk 4. De
neerslagkarakteristieken zijn sterk afhankelijk van het toegepaste type inhaler of
vernevelaar. Dosis-aerosolen worden gekenmerkt door een lagere luchtwegdepositie
van 10 tot 20% van de nominale dosis. Deze aerosolen blijken polydispers te zijn en
het grootste deel van de massa bestaat uit zeer grote deeltjes, welke in de bovenste
luchtwegen neerslaan. Voorzetkamers verlagen deze bovenste luchtwegdepositie,
hoewel hun effect sterk afhangt van het type kamer. Droge poeder inhalatoren missen
een aantal nadelen van de dosis-aerosolen, maar de effectiviteit ervan kan negatief
beïnvloed worden door lage inspiratoire krachten, die een patiënt soms op kan
brengen.
Slechts weinig experimenten hebben de relatie tussen de deeltjesgrootte en het
therapeutisch effect onderzocht en helaas zijn de uitkomsten ook nog met elkaar in
3tegenspraak. Sommige onderzoekers tonen géén verschil aan in effectiviteit voor
deeltjes <5 µm. Men concludeert dat de meest belangrijke factor een deeltjesgrootte
<5 µm is. Andere onderzoekers laten daarentegen zien dat 2.5 µm aerosolen sterker
werkzaam zijn dan 5 µm aerosolen. Vele factoren kunnen worden aangewezen voor
dit gebrek aan consensus. Zo gebruikte men diverse soorten vernevelaars, wat leidt
tot sterke verschillen in de toegediende doseringen en daarnaast waren de aerosolen
sterk polydispers. Beide factoren verlagen het onderscheidend vermogen van het
experiment en afhankelijk van de ernst van deze factoren rapporteerde men wel of
geen relatie tussen deeltjesgrootte en effectiviteit.
De resultaten van onze experimenten zijn opgenomen in hoofdstuk 6 t/m 10. In het
eerste experiment hebben 8 stabiele astmatici met een gemiddelde FEV1 van 72% van
de voorspelde waarde 3 monodisperse salbutamol-aerosolen geïnhaleerd (hoofdstuk
6). De deeltjesgrootten waren respectievelijk 1.5, 2.8 en 5 µm. Daarnaast werd een
placebo geïnhaleerd. De vrijwilligers inhaleerden een cumulatieve reeks van 5, 10, 20
en 40 µg salbutamol, waarna de toename van de longfunctie werd gemeten. De dosis-
respons curven zijn geanalyseerd d.m.v. repeated measurements anova. In geval van
de FEV1 en de MEF75/50/25 liet het 2.8 µm aërosol een sterkere luchtwegver ijding
zien dan het 5 µm aërosol, terwijl bij de piekstroom het 1.5 µm aërosol significant
zwakker was dan het 2.8 µm aërosol. In geval van de VC, de FVC en de
ademweerstand was er geen verschil in de luchtwegverwijding merkbaar t.g.v. van de
verschillende aerosol-typen. De conclusie van dit experiment was dat in deze milde
astmatici de optimale deeltjesgrootte voor ß2-mimetica aerosolen 2.8 µm is.
In het tweede experiment inhaleerden astmatici met een FEV1 >70% van de voors-
pelde waarde, monodisperse ipratropium bromide aerosolen met dezelfde deeltjes-
grootte als hierboven vermeld (hoofdstuk 7). De vrijwilligers inhaleerden nu 8 µg
ipratropium bromide, waarna op identieke wijze de longfunctietoename werd bepaald
en geëvalueerd. Wederom bleek bij de FEV1 en de MEF50/25 het 5 µm aërosol de
minst sterke luchtwegverwijding te zien te geven. In geval van de VC, FVC,
ademweerstand en de piekstroom was geen deeltjesgrootte effect merkbaar. Ook
voor parasympatholytische aerosolen is de optimale deeltjesgrootte 2.8 µm.
4Logischerwijze werd het volgende experiment uitgevoerd in patiënten met een
sterkere bronchusobstructie (hoofdstuk 8). Zeven stabiele patiënten met een
gemiddelde FEV1 van 37.9% van de voorspelde waarde hebben monodisperse
salbutamol en ipratropium bromide aerosolen geïnhaleerd met deeltjesgrootte
variërend van 1.5 tot 5 µm en wederom een placebo aerosol. De vrijwilligers
inhaleerden respectievelijk 20 µg salbutamol en 8 mg ipratropium bromide, waarna de
longfunctietoename werd bepaald en geëvalueerd op de gebruikelijke manier. Het 2.8
µm aerosol leidde tot een sterkere toename van de FEV1, specifieke
luchtwegconductantie en de MEF75/50 dan bij de andere deeltjesgrootten het geval
was. In patiënten met een sterke luchtwegobstructie blijkt de optimale deeltjesgrootte
voor zowel een ß2 mimeticum als een parasympatholytisch aërosol 2.8 µmte zijn.
Om te bezien of de luchtwegverwijdende effecten van deze laag gedoseerde
monodisperse aerosolen verschillen van de standaarddoseringen, zoals toegediend via
een dosis-aërosol, hebben wij een vergelijkende studie uitgevoerd (hoofdstuk 9). Tien
stabiele patiënten met een gemiddelde FEV1 van 58.1% van de voorspelde waarde
hebben een placebo aërosol, 8 µg ipratropium bromide als 2.8 µm monodispers
aërosol en 40 µg via een dosis-aërosol met voorzetkamer geïnhaleerd. Daarna is de
longfunctietoename bepaald en geanalyseerd middels repeated measurement anova.
Significante verbeteringen t.o.v. placebo werden waargenomen voor de FVC, de
FEV1, de specifieke luchtwegconductantie, de piekstroom en de MEF75. In al deze
gevallen was het laag gedoseerde 2.8 µm aerosol therapeutisch equivalent aan de
hoger gedoseerde dosis-aerosol. Het blijkt dus dat, wanneer men het polydisperse
karakter van geïnhaleerde aerosolen wijzigt naar een monodispers patroon, de
dosering van i halatie-middelen kan worden gereduceerd met minstens 80% zonder
effectiviteitsverlies.
Daarop hebben wij de bijwerkingen van 160 µg fenoterol als 2.8 µm monodispers
aerosol vergeleken met die van 800 µg fenoterol afkomstig uit een conventioneel
dosis-aërosol met voorzetkamer (hoofdstuk 10). Gezonde vrijwilligers, 8 vrouwen en
4 mannen, hebben deelgenomen aan deze proef en hebben in willekeurige volgorde
placebo, het monodisperse en het dosis-aerosol preparaat geïnhaleerd. De wijzigingen
in het plasmakaliumgehalte, vingertremor, bloeddruk, hartslag en specifieke
5luchtwegconductantie zijn gemeten voor en 15 minuten na de toediening van de
aerosolen. De beide actieve aerosolen lieten een significante toename zien van de
luchtwegconductantie n de bijwerkingen. Het serumkaliumgehalte nam na het
monodisperse aërosol af met 0.27 mmol/l, terwijl het dosis-aërosol een verlaging liet
zien van 0.67 mmol/l (p = 0.001). De vingertremor nam significant minder toe na toe-
diening van het monodisperse aërosol in vergelijking met het dosisa rosol. Wijziging
in de cardiovasculaire parameters waren niet significant t.o.v. placebo. Er waren geen
significante verschillen tussen de toename van de specifieke luchtwegconductantie
tussen de twee actieve preparaten. De conclusie is daarom dat een wijziging van de
formulering van dosis-aërosolen het mogelijk maakt bijwerkingen te reduceren.
Bespreking
De eerste hoofdconclusie van deze experimenten is dat bij patiënten met zowel milde
als sterkere luchtwegvernauwingen de optimale deeltjesgrootte voor ß2-mimetische en
parasympatholytische aerosolen 2.8 µm is. De tweede conclusie is dat toediening van
deze optimaal geformuleerde aerosolen een forse reductie van de dosering en het
aantal bijwerkingen mogelijk maakt.
De eerste conclusie kan worden verklaard door het bestaan van een ‘bovenste
luchtwegfilter’. De extrathoracale en bovenste luchtwegen functioneren als een
effectief filter voor grote deeltjes, waardoor de lagere luchtwegen beschermd worden
tegen een hogere belasting door stof of andere potentieel schadelijke stoffen.
Toediening van grote deeltjes is inefficiënt, omdat deze verloren gaan in dat bovenste
luchtwegfilter en lage doseringen in de lagere luchtwegen tot gevolg hebben. Dit
laatste staat gelijk aan een gering therapeutisch effect. Dit geldt zowel voor ß2-
mimetica als parasympatholytica en geeft de verklaring voor de lagere effectiviteit van
de 5 µm aerosolen. De berekening van de regionale depositie door Gerrity en
medewerkers zijn in dit geval van belang. Voor 5 µm aerosolen laten zij een
voornamelijk bovenste luchtweg depositie zien, terwijl deze in de lagere luchtwegen
veel lager is in vergelijking met 2 of 3 µm aerosolen. De experimentele gegevens van
Svartengren m.b.t. de afsnijpunten van de oropharynx onderstrepen het belang van dit
bovenste luchtwegfilter. Daarnaast dient men te realiseren dat zowel ß2-mimetisch
als parasympatholytische aerosolen in een zekere mate hygroscopisch zijn. Door
6vochtopname zal de grootte toenemen en daarmee de depositie in de bovenste
luchtwegen. Deeltjes van 5 µmnemen door hygroscopie veel sterker in grootte toe
dan 2.8 µm deeltjes, hetgeen de bovenste luchtwegdepositie alleen maar bevordert.
Na deze verklaring voor de lage effectiviteit van 5 mm aerosolen dienen de verschillen
tussen de 2.8 en 1.5 µm aerosolen nader verklaard te worden. Wij verwachtten dat
voor ß2-mimetische en parasympatholytische aerosolen, door verschillen in receptor-
verdeling, de optimale deeltjesgrootte zou verschillen. Voor parasympatholytische
aerosolen leek een centraal georiënteerd depositiepatroon logisch en de resultaten van
onze experimenten bevestigen dit, omdat 2.5 µm aerosolen sterker werkzaam zijn dan
1.5 µm aerosolen. Wellicht zou het depositiepatroon van 5 µm aerosolen nog beter
zijn in die zin, dat er een betere overeenstemming bestaat met de verdeling van de
receptoren. Echter de lage penetratie en daarmee dosering is kennelijk van groter
gewicht dan een betere overeenstemming met de receptorverdeling. Met andere
woorden een optimale afstemming tussen depositiepatroon en receptorverdeling is
van gering belang wanneer de gedeponeerde massa geneesmiddel erg laag is. Een
minder goed passend patroon met hogere massa's valt te prefereren.
Voor ß2-mimetica zou men kunnen verwachten dat 1.5 µm aerosolen een betere
keuze zouden zijn geweest, gelet op de betere overeenstemming van het
depositiepatroon met receptorverdeling. Dit bleek niet het geval te zijn en een aantal
verklaringen zijn hiervoor mogelijk. Ten eerste worden kleinere deeltjes altijd sterker
uitgeademd dan grotere deeltjes, ook bij astmatici. De experimenten door Schiller-
Scotland laten dit duidelijk zien. Haar gegevens toonden een tweemaal zo hoge
depositie van 3 mm deeltjes in vergelijking tot 1 µm deeltjes. 2.8 µm aerosolen
leveren altijd hogere lage luchtweg doseringen op en zijn daarmee sterker werkzaam.
Dosering lijkt van groter belang te zijn dan het depositiepatroon.
De gegevens van Gerrity tonen aan dat de depositiepatronen van 1, 2 en 3 µmdeeltjes
in de lagere luchtwegen niet zo sterk verschillen. De verspreiding van de deeltjes over
de luchtwegen is min of meer vergelijkbaar, maar de massa van 3 µ  deeltjes is veel
hoger. Wanneer depositiepatronen vergelijkbaar zijn, is de hoeveelheid massa die
deponeert van veel groter belang.
7De resultaten in sterk obstructieve patiënten kunnen worden verklaard door dezelfde
mechanismen. 5 µm deeltjes zullen de lagere luchtwegen niet bereiken. De effectiviteit
van het bovenste luchtwegfilter zal niet veel verschillen van die in minder obstructieve
astmatici of gezonde personen. Sterker nog, zelfs de geringste vernauwing in deze
regio zal het afsnijpunt van het filter verlagen, hetgeen betekent dat grote deeltjes in
nog mindere mate de lagere luchtwegen zullen bereiken. Men had kunnen verwachten
dat de 1.5 µm deeltjes in ‘versterkte’ mate in de vernauwde luchtwegen zouden door-
dringen en tot een groter effect zouden induceren, maar dit bleek niet het geval te
zijn. De depositie van 1.5 µm aerosolen zal altijd lager zijn dan die van 2.8 µm
aerosolen en blijkbaar bereiken de 2.8 µm aerosolen in voldoende mate de ß2-
receptor. De hogere neerslag van de 2.8 µm aerosolen is dan belangrijker.
In alle bovenstaande verklaringen speelt de chemische samenstelling van het
geneesmiddel nauwelijks een rol. Depositie van geïnhaleerde deeltjes is een fysisch
proces, welke niet verbonden is met de chemische structuur. De aërodynamische
deeltjesgrootte wordt niet beïnvloed door de chemische structuur, met een
uitzondering voor de hygroscopiciteit en de dichtheid van het deeltje. De dichtheid
speelt een ondergeschikte rol, omdat een toename van de dichtheid met een factor 8
de aërodynamische diameter slechts met een factor 2 doet toenemen. Dientengevolge
zal de bovenstaande relatie tussen deeltjesgrootte en effectiviteit waarschijnlijk voor
alle typen geneesmiddelen gelden, waarbij mogelijkerwijze een uitzondering gemaakt
moet worden voor receptorverdelingen die gelokaliseerd zijn in de bovenste
luchtwegen of in de alveoli.
Dosis-aerosolen en droge poeder inhalatoren genereren beide sterk polydisperse
aerosolen, waarbij er in de aërosolwolk veel grote deeltjes aanwezig zijn. Het is
daarom niet vreemd dat de lage luchtwegdepositie zo laag is en dat de dosering zo
sterk kan worden gereduceerd. Het overgrote deel van de afgegeven massa is simpel-
weg te groot om effectief te zijn. Die massa deponeert in de bovenste luchtwegen en
wordt daar of geabsorbeerd dan wel doorgeslikt en in het maag/darmkanaal
geabsorbeerd. Het gevolg van deze absorptie zijn systemische bijwerkingen.
Eliminatie van deze grote deeltjes reduceert de systemische belasting en daarmee
8bijwerkingen, hetgeen een redelijke verklaring is voor onze resultaten. Echter, elk
geneesmiddel, dat deponeert in de lage luchtwegen zal ook geabsorbeerd worden en
daarmee zijn enige systemische bijwerkingen onvermijdelijk. De ernst en de frequentie
van deze bijwerkingen zullen lager zijn, dan bij onze optimaal geformuleerde
aerosolen. De enige mogelijkheid om deze systemische bijwerkingen verder te
elimineren is een snelle deactivatie van het geabsorbeerde geneesmiddel. Deze
deactivatie moet echter geschieden voordat het geneesmiddel de receptor bezet,
hetgeen kan resulteren in een eis van een zeer snelle deactivatie.
Toekomstig onderzoek
Als de chemische structuur van de geneesmiddelen een weinig belangrijke rol voor
wat betreft de depositiepatronen speelt, zal voor corticosteroïden een optimale
deeltjesgrootte gelden, gelijksoortig aan luchtwegverwijders. Een sterke reductie van
de steroïdbijwerkingen ligt dan ook binnen de mogelijkheden. Er is echter één
parameter die verschilt van luchtwegverwijders. Luchtwegverwijders zijn alle
wateroplosbaar en daardoor hygroscopisch, terwijl steroïden hydrofoob zijn,
waardoor deeltjesgroei ten gevolge van wateropname minimaal of zelfs afwezig is.
Het is daarom mogelijk dat de relatie tussen deeltjesgrootte en effectiviteit minder
uitgesproken is bij steroïden. Dit vereist nader onderzoek.
Het zal duidelijk zijn dat het genereren van monodisperse aerosolen een vooruitgang
betekent in termen van therapeutische kwaliteit. Op dit moment zijn er diverse
mogelijkheden beschikbaar om een draagbare monodisperse aërosol generator te
vervaardigen. Enkele experimenten met de koppen van inkjet printers tonen aan dat
deze koppen in staat zijn monodisperse aerosolen te genereren, alhoewel het bleek dat
de druppels op dit moment nog te groot zijn voor inhalatie. Een wijziging in het
ontwerp van deze koppen moet het mogelijk maken kleinere druppels te genereren.
Aerosolen gebaseerd op het zogenaamde "Tayler cone" principe zijn een andere
mogelijkheid. Wanneer een slecht geleidende vloeistof door een stalen naald wordt
gepompt en deze naald verbonden is met een 10 kV bron, zal de vloeistof niet van de
punt van de naald afdruppelen maar een conus vormen. De hoge elektrische ladingen
dragen er nu zorg voor dat even grote druppeltjes de top van deze conus verlaten. De
grootte van deze druppeltjes wordt bepaald door een gering aantal parameters, welke
9alle eenvoudig gecontroleerd kunnen worden. Het hoge 10 kV voltage kan worden
opgebracht door simpele batterijen, omdat de stroom die verbruikt wordt erg laag is.
In de nabije toekomst moet het mogelijk zijn de technische problemen op te lossen en
te komen tot generatoren, die een beter gedefinieerd aerosol afgeven. De kwaliteit
van de anti-astma therapie kan hierdoor verhoogd worden.
Curriculum Vitae
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Dankwoord
De promovendus past bescheidenheid als men beziet hoeveel mensen er onontbeer-
lijk bleken te zijn voor het voltooien van een proefschrift. De onderstaande kring van
mensen verdienen een deel van de eer.
Drs. Ch. F. Gusdorf, beste Charles, weinigen zullen beseffen welke cruciale rol jij
hebt gespeeld in dit onderzoek. Het komt volgens mij zelden voor dat binnen de ge-
nerieke farmaceutische industrie de kans gegeven wordt een onderzoek als dit uit te
voeren. Jij hebt mij, zowel bij Pharbita als bij Genfarma, ruimhartig de gelegenheid
gegeven dit te doen. Het getuigt van groot inzicht, zonder dat was ik niet zover ge-
komen.
Dhr J. Kelders, beste Jan, wat voor Charles geldt, geldt in dubbele zin voor jou. Je
achtergrond en werkzaamheden hebben weinig relatie tot aerosol-onderzoek. Toch
heb je al die jaren het mogelijk gemaakt dat ik door kon gaan en niet omdat er een
‘gat in de markt zat’. Je grote Brabantse hart was het belangrijkst. Ik hoop dat jij nog
vele jaren mag genieten van een goede gezondheid.
Prof. Lammers, beste Jan-Willem, jij kwam naar Utrecht en ik was er al (eens per
week, beetje een buitenbeentje). Die enigszins curieuze positie heb je laten bestaan
en er kwam vertrouwen. Ik kon doorgaan en uitbouwen. Heel veel dank voor die
wijsheid.
Dhr. A Plomp, beste Adri, nog zo’n onbekend maar belangrijk figuur op de achter-
grond. Was jij er niet geweest dan was dit onderzoek nooit van de grond gekomen.
Jouw kennis van aerosolen en het geduld om mij de eigenschappen van de spinnig
top generator te leren, vormden de basis onder dit alles.
Dhr. T.L. Go, beste Liam, kamergenoot al deze jaren. Samen aan de opstelling ge-
werkt en hem aan de gang gekregen en gehouden. Ik zal niet vergeten hoe je als er
iets tegen zat, je de telefoon greep en begon te organiseren. Dames om te prikken
kwamen te voorschijn,  technische diensten begonnen te werken en de biologen
moesten maar even wachten.  Dank voor het er zijn en veel geluk in je verdere loop-
baan.
Drs. R. Otten, beste R ne, goede vriend. Literatuur is zo belangrijk, maar het is vaak
zo goed verstopt. Doch waar het ook was, jij wist het wel te achterhalen. Samen uren
achter die computer gezeten en ik hoop er nog vaak met je achter te zitten. Dank
daarvoor en ook voor de vele aang n me uren met Monique aan de eettafel.
Henny en Peter, de metingen van de longfunctie waren jullie toevertrouwd. Toen
wist ik er (nog) niet zoveel van af en vertrouwde op jullie vakkennis en inzet.  Die
laatste zijn groot en ik zie uit naar de volgende onderzoeken met jullie.
Lieve Edith, de eerste jaren met Justin zijn niet gemakkelijk geweest en vele zorgen
komen nog. Weinigen zullen beseffen hoe het ingrijpt om te weten dat je altijd voor
je kind zult moeten zorgen, ook als wij er niet meer zijn. Dat wij dat samen doen,
schept een band van staal tussen ons. Laten wij heel oud worden, dat zou mooi zijn.
Lieve Emmy, lieve Justin, stoere Friese dame en heerlijke zoon. Ik geniet van elke
dag dat jullie er zijn, ik zal jullie nog heel lang naar bed brengen en nog langer voor
jullie zorgen.
